DESCRIPTION

Title of the Invention: NOVEL SEVEN-MEMBERED RING-FUSED COMPOUNDS [Technical Field]

The present invention relates to a novel seven-membered ring- fused compounds. More specifically, the present invention relates to a novel seven-membered ring-fused compounds having Notch signal transduction inhibitory action.

[Background Art]

Notch signaling is an evolutionary conserved pathway that plays an integral role in development and tissue homeostasis in mammals . The Notch receptors and ligands contain single-pass transmembrane domains, are expressed on the cell surface and, for that reason, Notch signaling is particularly important in mediating communication between adjacent cells expressing the receptors and ligands. There are four known Notch receptors found in rodents and humans, termed Notch 1 to Notch 4. The Notch receptors are heterodimeric proteins composed of extracellular and intracellular domains that are initially synthesized as a single polypeptide. Receptor-ligand interaction triggers a series of proteolytic cleavages of the Notch receptor polypeptide in which γ-Secretase activity is involved. γ-Secretase activity cleaves Notch intracellular . domain from the internal side of the plasma membrane which translocates to the nucleus to form a transcription factor complex. Notch intracellular domain (NICD) is the active form of the protein. Various Notch signaling functions include proliferation, differentiation, apoptosis, angiogenesis, migration and self-renewal (Non-patent documents 1-3) .

In addition, NICD activates transcription of the target genes Hesl and Hes5 by translocation into the nucleus and forming a stable complex with RBP-J and MAML, which are DNA binding proteins .

Therefore, a compound that can inhibit various Notch signal function can be a medicament useful for various diseases involving the function. [Document List] [non-patent documents] non-patent document 1: Bray, Nature Reviews Molecular Cell Biology, 7 : 678-689 (2006) . non-patent document 2 : Fortini, Developmental Cell 16: 633-647 (2009) . non-patent document 3: Ables, J. L. et al. , Neurosci. , 12 : 269- 283 (2011) .

[SUMMARY OF THE INVENTION]

[Problems to be Solved by the Invention]

The present invention aims to provide a compound having a Notch signal transduction inhibitory action and a medicament containing the compound and useful for various diseases.

That is, the present invention relates to the following.

[1] A compound represented by the following formula (I) : wherein

Ri is represented by. any of the following formulas (I— 1) to (I- 2) :

* is a binding site with N (nitrogen atom) ; R _1a is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;

R _1b is hydrogen, optionally substituted alkyl or -W ₁₁ -W ₁₂ -R ₁₃ wherein W ₁₁ is - (CO) - or - (SO ₂ ) -, W ₁₂ is a single bond, -O- or -N (R ₁₄ ) -, R ₁₃ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl, R ₁₄ is hydrogen or optionally substituted alkyl, R ₁₃ and R ₁₄ may combine to form a saturated or unsaturated 4 to 7-membered ring, which may contain carbon atom, nitrogen atom, or oxygen atom, and an aryl ring or a heteroaryl ring may be fused to the ring, a substituent -X ₁₅ -R ₁₅ may be substituted on the formed saturated or unsaturated 4 to. 7 -membered ring or on the fused aryl ring or heteroaryl ring, X ₁₅ is -O-, -NH- or single bond, R ₁₅ is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl;

R _1c is optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;

R ₂ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl; m is 1 or 0;

L is -CH (R _9a ) - when m is 1, or -CH (R _9a ) -CH (R _9b ) - when m is 0; R _9a and R _9b are. independently hydrogen or optionally substituted alkyl;

R ₃ is — W ₃₁ — W ₃₂ — R ₃₃ wherein W ₃₁ is - (CO) -, - (SO ₂ ) -, or -CH ₂ - W ₃₂ is -O-, -NH-, or single bond, and R ₃₃ is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally . substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloal kylal kyl ; is represented by any of the following formulas (I-3) to (l-4) :

R _4a is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl ;

R _4b is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;

R _4a and R _4b optionally form a spiro ring together with a carbon bonded thereto, which optionally has oxygen atom or nitrogen atom in the ring; A is -CH (R ₅ ) -, -N (R ₅ ) -, -O- or single bond; R ₅ is hydrogen or optionally substituted alkyl; and ring B is an optionally substituted aryl ring, an optionally substituted heteroaryl ring, an optionally substituted cycloalkyl ring or an optionally substituted heterocycloalkyl ring; or a pharmaceutically acceptable salt thereof .

[2] The compound of [1] , wherein

A is -CH ₂ - or -O-; and ring B is an optionally substituted aryl ring or an optionally substituted heteroaryl ring; or a pharmaceutically acceptable salt thereof.

[3] The compound of [1] or [2] , wherein m is 1;

L is -CH (R _9a ) -; and

R _9a is hydrogen or methyl; or a pharmaceutically acceptable salt thereof .

[4] The compound of [1] or [2] , wherein m is 0;

L is -CH (R _9a ) -CH (R _9b ) -; and

R _9a and R _9b are independently hydrogen or methyl; or a pharmaceutically acceptable salt thereof .

[5] The compound of any one of [1] to [4] , wherein

R _1a is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl;

R _1b is hydrogen;

R _1c is optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and

R ₂ is hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl or optionally substituted cycloalkylalkyl; or a pharmaceutically acceptable salt thereof.

[6] The compound of any one of [1] to [5] , wherein

R _4a is hydrogen, optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted cycloalkylalkyl; R _4b is hydrogen or optionally substituted alkyl; and

R _4a and R _4b optionally form a spiro ring together with a carbon bonded thereto, which optionally has oxygen atom or nitrogen atom in the ring; or a pharmaceutically acceptable salt thereof .

[7] The compound of any one of [1] to [3] , [5] and [6] , wherein A is -CH ₂ - or -O-; ring B is an optionally substituted aryl ring or an optionally substituted heteroaryl ring; m is 1;

L is -CH (R _9a ) -;

R _9a is hydrogen or methyl; R _1a is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl;

R _1b is hydrogen;

R _1c is optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;

R ₂ is hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl or optionally substituted cycloalkylalkyl;

R _4a is hydrogen, optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted cycloalkylalkyl; R _4b is hydrogen or optionally substituted alkyl; and

R _4a and R _4b optionally form a spiro ring together with a carbon bonded thereto, which optionally has oxygen atom or nitrogen atom in the ring; or a pharmaceutically acceptable salt thereof.

[8] The compound any one of [1] , [2] and [4] to [6] , wherein A is -CH ₂ - or -O-; ring B is an optionally substituted aryl ring or an optionally substituted heteroaryl ring; m is 0;

L is -CH (R _9a ) -CH (R _9b ) -;

R _9a and R _9b are independently hydrogen or methyl; R _1a is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl;

R _1b is hydrogen;

R _1c is optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;

R ₂ is hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl or optionally substituted cycloalkylalkyl;

R _4a is hydrogen, optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted cycloalkylalkyl;

R _4b is hydrogen or optionally substituted alkyl; and

R _4a and R _4b optionally form a spiro ring together with a carbon bonded thereto, which optionally has oxygen atom or nitrogen atom in the ring; or a pharmaceutically acceptable salt thereof.

[9] A pharmaceutical composition comprising a compound of any one of [1] to [8] or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier or diluent.

[10] The pharmaceutical composition of [9] , wherein the composition comprises an effective amount of the compound.

[11] A method of treating or preventing a disease involving Notch signal transduction comprising administering to a subject in need thereof the compound of [1] to [8] or a pharmaceutically acceptable salt thereof, or the composition of [9] or [10] , in an amount effective to treat or prevent the disease.

[12] An agent for treating or preventing a disease involving Notch signal transduction comprising the compound of any one of [1] to [8] or a pharmaceutically acceptable salt thereof .

[13] The compound of any one of [1] to [8] or a pharmaceutically acceptable salt thereof, or the composition of [9] or [10] for the use as a medicament for treating or preventing a disease involving Notch signal transduction.

[Effect of the Invention] The compound of the formula (I) of the present invention inhibits Notch signal transduction and thus can be used for treating various diseases involving Not ch . signal transduction. [Brief Description of the Drawings] [Fig. 1] Fig. 1 shows a ¹ H NMR (400 MHz, CDCI ₃ ) data of D-8. [Fig. 2] Fig. 2 shows a ¹ H NMR (400 MHz, CDCI ₃ ) data of D-10. [Fig. 3] Fig. 3 shows a ¹ H NMR (400 MHz, CDCI ₃ ) data of ID-39.

[Description of Embodiments] Definition

Unless otherwise stated, the following terms used in the specification and claims shall have the following meanings for the purposes of this Application.

"Lower", unless indicated otherwise, means that the number of the carbon atoms constituting the given radicals is between one and six.

"Optionally substituted", unless otherwise stated, means that a given radical may consist of only hydrogen substituents through available valencies or may further comprise one or more non-hydrogen substituents through available valencies . In general, a non-hydrogen substituent may be any substituent that may be bound to an atom of the given radical that is specified to be substituted. Examples of substituents include, but are not limited to, -R ₆ , -OR ₆ , -COR ₆ , -COOR ₆ , -OCOR ₆ , -CONR ₆ R ₇ , -NR ₆ R ₇ , - NR ₇ COR ₆ , -NR ₇ COOR ₆ , -SR ₆ , -SO ₂ R ₆ , -SO ₂ NR ₆ R ₇ , -SO ₂ OR ₆ , -OSO ₂ R ₆ , - NHC (NHR ₆ ) NR ₇ , -NHC (NH ₂ ) NH, -CN, -NO ₂ , halogen and methylenedioxy, wherein R ₆ and R ₇ is independently selected from hydrogen, . linear or branched chain, cyclic or noncyclic, substituted or unsubstituted, alkyl chain, aryl, heteroaryl, arylalkyl and heteroarylalkyl moieties.

"Halogen" means fluorine, chlorine, bromine or iodine. "Halo" means fluoro, chloro, bromo or iodo.

"Alkyl" means a linear or branched, saturated, aliphatic radical having a chain of carbon atoms. C _X-Y alkyl is typically used where X and Y indicate the number of carbon atoms in the chain . The number of carbon atoms in the chain is preferably 1 to 10, more preferably 1 to 6 (C _1-6 ) , further preferably 1 to 4 (C _1-4 ) . Non-exclusive examples of alkyl include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, and. the like.

"Alkenyl" means a linear or branched, carbon chain that contains at least one carbon-carbon double bond. C _X-Y alkenyl is typically used where X and Y indicate the number of carbon atoms in the chain. The number of carbon atoms in the chain is preferably 2 to 10 (C _2-10 ) , more preferably 2 to 6 (C _2-6 ) - Nonexclusive examples of alkenyl include ethenyl (vinyl) , allyl, isopropenyl, 2 -methylallyl, 1 -pentenyl, hexenyl, heptenyl, 1- propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.

"Alkynyl" means a linear or branched, carbon chain that contains at least one carbon-carbon triple bond. C _X-Y alkynyl is typically used where X and Y indicate the number of carbon atoms in the chain. The number of carbon atoms in the chain is preferably 2 to 10 (C _2-10 ) , more preferably 2 to 6 (C _2-6 ) - Nonexclusive examples of alkynyl include ethynyl, propargyl, 3- methyl-l-pentynyl, 2-heptynyl and the like.

"Alkylene", unless indicated otherwise, means a linear or branched, saturated, aliphatic, polyvalent carbon chain. C _X-Y alkylene is typically used where X and Y indicate the number of carbon atoms in the chain. The number of carbon atoms in the chain is preferably 1 to 10 (C1-10) , more preferably 1 to 6 (C _1-6 ) . Non-exclusive examples of alkylene include methylene (-CH ₂ -) , ethylene (-CH ₂ CH ₂ -) , methylmethylene (-CH (CHa) -) , 1, 2-propylene (-CH ₂ CH (CH3) -) , 1, 3-propylene (-CH ₂ CH ₂ CH ₂ -) , 1, 2-butylene (- CH ₂ CH (CH ₂ CH ₃ ) -) , 1, 3-butylene (-CH ₂ CH ₂ CH (CH ₃ ) -) , 1, 4 -butylene (- CH ₂ CH ₂ CH ₂ CH ₂ -) , 2-methyltetramethylene (-CH ₂ CH (CH ₃ ) CH ₂ CH ₂ -) , pentamethylene (-CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ -) , 1, 2, 3-propanetriyl, 1, 3, 3- propanetriyl and the like.

"Heteroatom" refers to an atom that is not a carbon atom and hydrogen atom. Particular examples of heteroatoms include, but are not limited to nitrogen, oxygen, and sulfur.

"Aryl" means a monocyclic or polycyclic radical wherein each ring is aromatic or when fused with one or more rings forms an aromatic ring. C _X-Y aryl is typically used where X and Y indicate the . number of carbon atoms in the ring assembly. The number of carbon atoms in the ring is preferably 6 to 14 (C _6-14 ) , more preferably 6 to 10 (C _6-10 ) - Non-exclusive examples of aryl include phenyl, naphthyl, indenyl, azulenyl, biphenyl ,_ fluorenyl, anthracenyl, phenalenyl and the like. "Aryl" may partially be hydrogenated. Non-exclusive examples of partially hydrogenated aryl include tetrahydronaphthyl, indanyl and the like.

"Heteroaryl" means a monocyclic or polycyclic aromatic radical wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon. "X-Y membered heteroaryl" is typically used where X and Y indicate the number of carbon atoms and heteroatoms in the ring assembly. The number of carbon atoms and heteroatoms in the ring is preferably 5 to 14, more preferably 5 to 10. Monocyclic heteroaryl groups include, but are not limited to, cyclic aromatic groups having five or six ring atoms, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon. The nitrogen atoms can be optionally quaternerized and the sulfur atoms can be optionally oxidized. Non-exclusive examples of monocyclic heteroaryl group of this invention include, but are not limited to, those derived from furan, imidazole, isothiazole, isoxazole, oxadiazole, oxazole, 1, 2, 3-oxadiazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, 1, 3, 4 -thiadiazole, triazole and tetrazole. "Heteroaryl" also includes, but is not limited to, bicyclic or tricyclic rings, wherein the heteroaryl ring is fused to one or two rings independently selected from the group consisting of an aryl ring, a cycloalkyl ring, and another monocyclic heteroaryl of heterocycloalkyl ring. Nonexclusive examples of bicyclic or tricyclic heteroaryl include, but are not limited to, those derived from benzofuran (ex. benzo [b] furan) , benzothiophene (ex. benzo [b] thiophene) , benzimidazole, benzotriazine (ex. benzo [e] [1, 2, 4] triazine, benzo [d] [1, 2, 3] triazine) , pyridopyrimidine (ex. pyrido [4, 3- d] pyrimidine, pyrido [3, 4-d] pyrimidine, pyrido [3, 2-d] pyrimidine, pyrido [2, 3-d] pyrimidine) , pyridopyrazine (ex. pyrido [3, 4- b]pyrazine, pyrido [2, 3 -b] pyrazine) , pyridopyridazine (ex. pyrido [2, 3-c] pyridazine, pyrido [3, 4-c] pyridazine, pyrido [4, 3- c] pyridazine, pyrido [3, 2-c] pyridazine) , pyridotriazine (ex. pyrido [2, 3-d] [1, 2, 3] triazine, pyrido [3, 4-d] [1, 2, 3] triazine, pyrido [4, 3-d] [1, 2, 3] triazine, pyrido [3, 2-d] [1, 2, 3] triazine, pyrido [3, 4-e] [1, 2, 4] triazine, pyrido [3, 2-e] [1, 2, 4] triazine) , benzothiadiazole (ex. benzo [c] [1, 2, 5] thiadiazole) , furopyridine (ex. furo [3, 2 -b] pyridine, furo [3, 2 -c] pyridine, furo [2, 3- c]pyridine, furo [2, 3-b] pyridine) , oxazolopyridine (ex. oxazolo [4, 5-b] pyridine, oxazolo [4, 5-c] pyridine, oxazolo [5, 4- c]pyridine, oxazolo [5, 4 -b] pyridine) , thiazolopyridine (ex. thiazolo [4, 5-b] pyridine, thiazolo [4, 5-c] pyridine, thiazolo [5, 4- c]pyridine, thiazolo [5, 4 -b] pyridine) , imidazopyridine (ex. imidazo [1, 2-a] pyridine, imidazo [4, 5-c] pyridine, imidazo [1, 5- a]pyridine) , quinazoline, thienopyridine (ex. thieno [2, 3- c]pyridine, thieno [3, 2-b] pyridine, thieno [2, 3-b] pyridine) , indolizine, quinoline, isoquinoline, phthalazine, quinoxaline, cinnoline, naphthyr idine, quinolizine, indole, isoindole, indazole, indoline, benzoxazole, benzopyrazole, benzothiazole, pyrazolopyridine (ex. pyrazolo [1, 5-a] pyridine) , imidazopyrimidine (ex. imidazo [1, 2 -a] pyrimidine, imidazo [1, 2- c]pyrimidine, imidazo [1, 5-a] pyrimidine, imidazo [1, 5- c] pyrimidine) , pyrrolopyridine (ex. pyrrolo [2, 3-b] pyridine, pyrrolo [2, 3-c] pyridine, pyrrolo [3, 2 -c] pyridine, pyrrolo [3, 2- b] pyridine) , pyrrolopyrimidine (ex. pyrrolo [2, 3-d] pyrimidine, pyrrolo [ 3 , 2 -d ] pyrimidine , pyrrolo [ 1 , 2 -c ] pyrimidine , pyrrolo [1, 2— a ] pyrimidine ) , pyrrolopyrazine (ex. pyrrolo [2, 3-b] pyrazine, pyrrolo [1, 2-a] pyrazine) , pyrrolopyridazine (ex. pyrrolo [1, 2- b]pyridazine) , triazopyridine (ex. triazo [1, 5-a] pyridine) , pteridine, purine, carbazole, acridine, perimidine, 1, 10- phenenthroline, phenoxathiin, phenoxazine, phenothiazine, phenazine and the like. The bicyclic or tricyclic heteroaryl rings can be attached to the parent molecule through either the heteroaryl group itself or the aryl, cycloalkyl, or heterocycloalkyl group to which it is fused.

"Cycloalkyl" means a non-aromatic, saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring radical. C _X-Y cycloalkyl is typically used where X and Y indicate the number of carbon atoms in the ring assembly, The number of carbon atoms in the ring is preferably 3 to 10 (C _3-10 ) , more preferably 3 to 8 (C _3-8 ) . Non-exclusive examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2, 5-cyclohexadienyl, bicyclo [2.2.2] octyl, adamantan-l-yl, decahydronaphthyl, bicyclo [2.2.1] hept-l-yl, and the like.

"Heterocycloalkyl" means cycloalkyl, as defined in this Application, provided that one or more of the atoms forming the ring is a heteroatom selected, independently from N, 0, or S. "X-Y membered heterocycloalkyl" is typically used where X and Y indicate the number of carbon atoms and heteroatoms in the ring assembly. The number of carbon atoms and heteroatoms in the ring is preferably 3 to 10, more preferably 3 to 8. Nonexclusive examples of heterocycloalkyl include piperidyl, 4- morpholinyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolidinyl,

1. 4-diazaperhydroepinyl, 1, 3-dioxanyl, 1, 4-dioxanyl, and the like.

Moreover, the above-mentioned definitions can apply to groups wherein the above-mentioned substituents are connected. For example, "arylalkyl" means linear or branched alkyl group which is substituted by one or more aryl groups, such as benzyl,

1 -phenylethyl, 2-phenylethyl, 3 -phenylpropyl, 1 -naphthylmethyl,

2 -naphthylmethyl and the like. "Heteroarylalkyl" means linear or branched alkyl group which is substituted by one or more heteroaryl groups.

"Cycloalkylalkyl" means linear or branched alkyl group which is substituted by one or more cycloalkyl group (e.g. , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl,

2. 5-cyclohexadienyl, bicyclo [2.2.2] octyl, adamantan-l-yl, decahydronaphthyl , bicyclo [2.2.1] hept-l-yl ) .

"Heterocycloalkylalkyl" means linear or branched alkyl group which is substituted by one or more heterocycloalkyl groups .

"Monocyclic ring" as used herein refers to a monocyclic, saturated or unsaturated carbocyclic ring or a monocyclic, saturated or unsaturated heterocyclic ring. "X-membered monocyclic ring" is typically used where X indicate the number of carbon atoms and heteroatoms in the ring assembly. The number of carbon atoms and heteroatoms in the ring is preferably 4 to 7, more preferably 5 or 6. "Monocyclic heterocyclic ring" means a monocyclic, aromatic or nonaromatic ring wherein at least one ring atom is a heteroatom (preferably S, N or 0) and the remaining ring atoms are carbon. The nitrogen atoms can be optionally quaternerized and the sulfur atoms can be optionally oxidized.

Non-exclusive examples of monocyclic saturated carbocyclic ring include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane and the like.

Non-exclusive examples of monocyclic unsaturated carbocyclic ring include cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclopentadiene, benzene, and the like.

Non-exclusive examples of monocyclic saturated heterocyclic ring include pyrrolidine, piperidine, morpholine, piperazine, 1, 3-dioxane, 1, 4-dioxane and the like.

Non-exclusive examples of monocyclic unsaturated heterocyclic ring include pyrazole, dihydro-pyrrole, pyrrole, dihydro-pyrazole, imidazole, thiophene, thiazole, isothiazole, thiadiazole, furan, oxazole, isoxazole, oxadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine and the like.

"Spiro ring" as used herein refers to saturated or unsaturated cycloalkane or saturated or unsaturated heterocycloalkane.

"Cycloalkane" means a non-aromatic, saturated or. partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring. C _X-Y cycloalkane is typically used where X and Y indicate the number of carbon atoms in the ring assembly. The number of carbon atoms in the ring is preferably 3 to 10 (C _3-10 ) , more preferably 3 to 8 (C _3-8 ) . Non-exclusive examples of cycloalkane include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane and the like.

"Heterocycloalkane" means cycloalkane, as defined in this Application, provided that one or more of the atoms forming the ring is a heteroatom selected, independently from N, 0, and S. "X-Y membered heterocycloalkane" is typically used where X and Y indicate the number of carbon atoms and heteroatoms in the ring assembly. The number of carbon atoms and heteroatoms in . the ring is preferably 3 to 10, more preferably 3 to 8. Nonexclusive examples of heterocycloalkane include piperidine, morpholine, piperazine, pyrrolidine, perhydropyrrolizine, tetrahydrofuran, tetrahydropyran, 1, 3-dioxane, 1, 4-dioxane and the like.

"A saturated or unsaturated 4 to 7 -membered ring", means 4 to 7-memberd one among the above-mentioned monocyclic ring.

"Protected derivatives" means derivatives of compound in which a reactive site or sites are blocked with protecting groups. A comprehensive list of suitable protecting groups can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 5th edition, John Wiley&Sons, Inc.2014.

"Isomers" mean any compound having identical molecular formulas but differing in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers" and stereoisomers that are nonsuperimposable mirror images are termed "enantiomers" or sometimes "optical isomers". A carbon atom bonded to four nonidentical substituents is termed a "chiral center". A compound with one chiral center has two enantiomeric forms of opposite chirality. A mixture of the two enantiomeric forms is termed a "racemic mixture". A compound that has more than one chiral center has 2 ^n-1 enantiomeric pairs, where n is the number of chiral centers . Compounds with more than one chiral center may exist as either an individual diastereomer or as a mixture of diastereomers, termed a "diastereomeric mixture". When one chiral center is present a stereoisomer may be characterized by the absolute configuration of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and S-sequencing rules of Cahn, Ingold and Prelog. Conventions for stereochemical nomenclature, methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (e. g. , see "Advanced Organic Chemistry", 4th edition, March, Jerry, John Wiley & Sons, New York, 1992) . The compounds of the present invention may include these isomers. "Animal" includes humans, non-human mammals (e. g. mice, rats, dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e. g. , birds, and the like) . "Disease" specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition that may be caused by, or incident to, medical or veterinary therapy applied to that animal, i. e. , the "side effects" of such therapy.

"Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.

"Pharmaceutically acceptable salt" or "salt" means salts of compounds of the present invention which are pharmaceutically . acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o- (4- hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulf onic . acid, ethanesulfonic acid, 1,2 -ethanedisulfonic acid, 2-hydrOxyethanesulfonic acid, benzenesulfonic acid, p- chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p- toluenesulfonic acid, camphorsulfonic acid, 4- methylbicyclo [2.2.2] oct-2-ene-l-carboxylic acid, glucoheptonic acid, 4, 4 ' -methylenebis (3-hydroxy-2-ene-l-carboxylic acid) , 3- phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, trifluoroacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like.

Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable, of reacting with inorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like.

"Amount effective to treat" means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.

"Amount effective to prevent" means that amount which, when administered to an animal for preventing a disease, is sufficient to effect such prophylaxis for the disease.

"Effective amount" equals to "amount effective to treat" and "amount effective to prevent".

"Treatment" or "treat" means any administration of a compound of the present invention and includes:

(1) preventing the disease from occurring in an animal which may be predisposed to the. disease but does not yet experience or display the pathology or symptomatology of the disease,

(2) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e. , arresting further development of the pathology and/or symptomatology) , or

(3) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e. , reversing the pathology and/or symptomatology) .

It is noted in regard to all of the definitions provided herein that the definitions should be interpreted as being open ended in the sense that further substituents beyond those specified may be included.

In the present invention, a compound represented by the following formula (I) :

wherein

R ₁ is represented by any of the following formulas (l-1) to (I- 2) :

* is a binding site with N (nitrogen atom) ; R _1a is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted .cycloalkylalkyl or optionally substituted heterocycloal kylalkyl ;

R _1b is hydrogen, optionally substituted alkyl or -W ₁₁ -W ₁₂ -R ₁₃ wherein

W ₁₁ is - (CO) - or - (SO ₂ ) -,

W ₁₂ is a single bond, -O- or -N (R ₁₄ ) -,

R ₁₃ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl, R ₁₄ is hydrogen or optionally substituted alkyl, R ₁₃ and R ₁₄ may combine to form a saturated or unsaturated 4 to 7 -membered ring, which may contain carbon atom, nitrogen atom, or oxygen atom, and an aryl ring or a heteroaryl ring may be fused to the ring, a substituent -X ₁₅ -R ₁₅ may be substituted on the formed saturated or unsaturated 4 to 7 -membered ring or on the fused aryl ring or heteroaryl ring, X ₁₅ is — 0— , -NH- or single bond, R ₁₅ is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl;

R _1c is optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;

R ₂ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloal kylal kyl ; m is 1 or 0;

L is -CH (R _9a ) - when m is 1, or -CH (R _9a ) -CH (R _9b ) - when m is 0; R _9a and R _9b are independently hydrogen or optional substituted alkyl;

R ₃ is -W ₃₁ -W ₃₂ -R ₃₃ . ' wherein W ₃₁ is - (CO) -, - (SO ₂ ) -, or -CH ₂ -

• W ₃₂ is -O-, -NH-, or single bond, and R ₃₃ is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl; is represented by any of the following formulas (l-3) to (l-4) :

R _4a is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylal kyl ;

R _4b is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally . substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;

R _4a and R _4b optionally form a spiro ring together with a carbon bonded thereto, which optionally has oxygen atom or nitrogen atom in the ring;

A is -CH (R ₅ ) -, -N (R ₅ ) -, -O- or single bond; R ₅ is hydrogen or optionally substituted alkyl; and ring B is an optionally substituted aryl ring, an optionally substituted heteroaryl ring, an optionally substituted cycloalkyl ring or an optionally substituted heterocycloalkyl ring; or a pharmaceutically acceptable salt thereof, is disclosed.

In one embodiment of the formula (I) , R _1a is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted heterocycloalkylalkyl .

Examples of optionally substituted alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert -butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methyl thiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl, guanidinomethyl, guanidinoethyl, guanidinopropyl and the like.

Examples of optionally substituted alkenyl group include ethenyl, allyl, 1 -propenyl, 2 -methylallyl and the like.

Examples of optionally substituted alkynyl group include ethynyl, 1-propynyl, and the like.

Examples of optionally substituted aryl and optionally substituted heteroaryl include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyr idinyl, benzotriazinyl, indenyl, pyr idopyr imidinyl , pyr idopyra z inyl , pyr idopyr ida z iny l , pyridotriazinyl, benzofuryl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, furopyr idinyl, thienopyridinyl, pyrropyr idinyl, oxazolopyr idinyl, thia zolopyr idinyl, imidazopyr idinyl and the like.

Examples of optionally substituted cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and the like.

Examples of optionally substituted heterocycloalkyl include piperidyl, 4-morpholinyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolidinyl, 1, 3-dioxanyl, 1, 4-dioxanyl, tetrazolyl, acetylpiperidinyl and the like. Examples of the optionally substituted arylalkyl group include unsubstituted arylalkyl or arylalkyl having an alkyl group such as benzyl, α-methylbenzyl, phenethyl, α- methylphenethyl , α , α-dimethylbenzyl , α , α-dimet hy Iphenethy 1 , 4- methylphenethyl, 4 -methylbenzyl, 4 -isopropylbenzyl and the like; arylalkyl having an aryl group or an arylalkyl group such as 4- benzylbenzyl, 4 -phenethylbenzyl, 4-phenylbenzyl and the like; arylalkyl having a substituted oxy group such as 4 -methoxybenzyl,

4-n-tetradecyloxybenzyl, 4-n-heptadecyloxybenzyl, 3, 4- dimethoxybenzyl, 4 -methoxymethylbenzyl, 4 -vinyl oxymethylbenzyl, 4 -benzyloxybenzyl, 4 -phenethyloxybenzyl and the like; arylalkyl having a hydroxyl group such as 4 -hydroxybenzyl, 4-hydroxy-3- methoxybenzyl and the like; arylalkyl having a halogen atom such as 4 -fluorobenzyl, 3-chlorobenzyl, 3, 4 -di chlorobenzyl and the like; diphenylmethyl, diphenylpropyl, 1 -naphthylmethyl, 2- naphthylmethyl and the like.

Examples of the optionally substituted heteroarylalkyl group include 2-furfuryl, 2-benzodioxolylmethyl, 3- benzodioxolylmethyl, 2 -thienylmethyl, 3-thienylmethyl, 2- pyridylmethyl, 3-pyridylmethyl, 2-pyrimidinylmethyl, 5- pyrimidinylmethyl, 3-pyridazinylmethyl, 2-indolylmethyl, 5- indolylmethyl, 2 -benzof uranylmethyl, 5-indolylmethyl, 2- benzothienylmethyl , 5 -benzothienylmethyl , 6-f luoro-2- benzof uranylmethyl , 6-chloro-2-benzof uranylmethyl, 6-methoxy-2- benzof uranylmethyl , 6-f luoro-2-benzothienylmethyl , 6-chloro-2- benzothienylmethyl , 6-methoxy-2-benzothienylmethyl, 6-phenyl-3- pyridazinylmethyl and the like.

Examples of the optionally substituted cycloalkylalkyl group include cyclopropylmethyl, fluorocyclopropylmethyl, chlorocyclopropylmethyl , bromocyclopropylmethyl , iodocyclopropylmethyl, methylcyclopropylmethyl, 1, 1- dimethyl cyclopropylmethyl, 1, 2-dimethylcyclopropylmethyl, hydr oxycyclopropy Imethy 1 , methoxycyclopr opy Imet hyl , ethoxycyclopropylmethyl , methoxycarbonylcyclopropylmethyl , methylcarbamoylcyclopropylmethyl, cyclopropylethyl, cyclohexylmethyl, cyclopropylhexyl and the like. . Examples of the optionally substituted heterocycloal kylalkyl group include (2-tetrahydrofuryl) methyl, (2-tetrahydrothiof uranyl) methyl and the like.

In another embodiment of the formula (I) , R _1a is hydrogen, optionally substituted alkyl (e.g. , isobutyl, propyl, aminopropyl) , optionally substituted aryl (e.g. , naphthyl, phenyl) , optionally substituted heteroaryl (e.g. , quinolinyl, pyridyl) , optionally substituted cycloalkyl (e.g. , cyclohexyl) , optionally substituted arylalkyl (e.g. , benzyl) , optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl.

In further another embodiment of the formula (I) , R _1a is hydrogen, optionally substituted alkyl (e. g. , isobutyl, propyl, aminopropyl) , optionally substituted aryl (e.g. , naphthyl, phenyl) , optionally substituted heteroaryl (e. g. , quinolinyl, pyridyl) , optionally substituted cycloalkyl (e.g. , cyclohexyl) , optionally substituted arylalkyl (e.g. , benzyl) .

In one embodiment of the formula (I) , R _1b is hydrogen, optionally substituted alkyl or -W ₁₁ -W ₁₂ -R ₁₃ wherein

W ₁₁ is - (CO) - or - (SO ₂ ) -,

W ₁₂ is a single bond, -O- or -N (R ₁₄ ) -,

R ₁₃ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl, R ₁₄ is hydrogen or optionally substituted alkyl,

R ₁₃ and R ₁₄ may combine to form a saturated or unsaturated 4 to 7- membered ring, which may contain carbon atom, nitrogen atom, or oxygen atom, and an aryl ring or a heteroaryl ring may be fused to the ring, a substituent -X ₁₅ -R ₁₅ may be substituted on the formed saturated or unsaturated 4 to 7 -membered ring or on the fused aryl ring or heteroaryl ring, X ₁₅ is -O-, -NH- or single bond, R ₁₅ is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.

Examples of optionally substituted alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert -butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methyl thiomethyl, methylthioethyl, methyl thiopropyl, methyl thiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl, guanidinomethyl , guanidinoethyl, guanidinopropyl and the like.

Examples of optionally substituted alkenyl group include ethenyl, allyl, 1 -propenyl, 2 -methylallyl and the like.

Examples of optionally substituted alkynyl group include ethynyl, 1-propynyl, and the like.

Examples of optionally substituted aryl and optionally substituted heteroaryl include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuryl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, furopyridinyl, thienopyridinyl, pyrropyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridinyl and the like.

Examples of optionally substituted cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamant yl and the like.

Examples of optionally substituted heterocycloalkyl include piperidyl, 4-morpholinyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolidinyl, 1, 3-dioxanyl, 1, 4-dioxanyl, tetrazolyl, and the like. Examples of the optionally substituted arylalkyl group include unsubstituted arylalkyl or arylalkyl having an alkyl group such as benzyl, α-methylbenzyl, phenethyl, α- methylphenethyl, α , α-dimethylbenzyl, α , α-dimethylphenethyl, 4- methylphenethyl, 4 -methylbenzyl, 4-isopropylbenzyl and the like; arylalkyl having an aryl group or an arylalkyl group such as 4- benzylbenzyl, 4 -phenethylbenzyl, 4 -phenylbenzyl and the like; arylalkyl having a substituted oxy group such as 4 -methoxybenzyl, 4-n-tetradecyloxybenzyl, 4 -n-heptadecyl oxybenzyl, 3, 4- dimethoxybenzyl, 4 -methoxymethylbenzyl, 4-vinyloxymethylbenzyl, 4 -benzyloxybenzyl, 4 -phenethyloxybenzyl and the like; arylalkyl having a hydroxyl group such as 4 -hydroxybenzyl, 4 -hydroxy- 3- methoxybenzyl and the like; arylalkyl having a halogen atom such as 4 -fluorobenzyl, 3-chlorobenzyl, 3, 4 -dichlorobenzyl and the like; diphenylmethyl, diphenylpropyl, 1 -naphthylmethyl, 2- naphthylmethyl and the like.

Examples of the optionally substituted heteroarylalkyl group include 2-furfuryl, 2-benzodioxolylmethyl, 3- benzodioxolylmethyl, 2 -thienylmethyl, 3-thienylmethyl, 2- pyridylmethyl, 3-pyridylmethyl, 2-pyrimidinylmethyl, 5- pyrimidinylmethyl, 3-pyridazinylmethyl, 2-indolylmethyl, 5- indolylmethyl, 2 -benzof uranylmethyl, 5-indolylmethyl, 2- benzothienylmethyl, 5-benzothienylmethyl, 6-fluoro-2- benzof uranylmethyl , 6-chloro-2-benzof uranylmethyl, 6-methoxy-2- benzof uranylmethyl , 6- f luoro-2 -benzothienylme thyl , 6-chloro-2 - benzothienylmethyl , 6-methoxy-2-benzothienylmethyl, 6-phenyl-3- pyridazinylmethyl and the like.

Examples of the optionally substituted cycloalkylalkyl group include cyclopropylmethyl, fluorocyclopropylmethyl, chlorocyclopropylmethyl , bromocyclopropylmethyl , iodocyclopropylmethyl, methylcyclopropylmethyl, 1, 1- dimethylcyclopropylmethyl , 1, 2 -dimethyl cyclopropylmethyl , hydroxycyclopropylmethyl, . methoxycyclopropylmethyl, ethoxycyclopropylmethyl , methoxycarbonylcyclopropylmethyl , methylcarbamoylcyclopropylmethyl , cyclopropylethyl , cyclohexylmethyl, cyclopropylhexyl and the like. Examples of the optionally substituted heterocycloalkylalkyl group include (2-tetrahydrofuryl) methyl, (2-tetrahydrothiof uranyl) methyl and the like.

Examples of the saturated or unsaturated 4 to 7-membered ring, which may contain carbon atom, nitrogen atom, or oxygen atom include a hydrocarbon ring such as benzene, tropilidene, cyclopentane, cyclohexane, cycloheptane, 1 -cyclopentene, 2- cyclopentene, 3 -cyclopentene, 1-cyclohexene, 2 -cyclohexene, 3- cyclohexene, 1 -cycloheptene, 2 -cycloheptene, 3-cycloheptene,

2. 4 -cycloheptadiene, etc. and a heterocyclic ring such as pyridine, pyrazine, pyrimidine, imidazole, furan, thiophene, dihydropyridine, diazepine, oxazepine, pyrrolidine, piperidine, hexamethyleneimine, heptamethyleneimine, tetrahydrofuran, piperazine, homopiperazine, tetrahydroxazepine, morpholine, thiomorpholine, pyrrole, pyrazole, 1, 2, 3-triazole, oxazole, oxazolidine, thiazole, thiazolidine, isoxazole, imidazoline, triazole, thiadiazole, oxadiazole, oxathiadiazole, triazine, etc. and the like.

An aryl ring or a heteroaryl ring may be fused to the saturated or unsaturated 4 to 7 -membered ring.

Examples of the aryl ring include benzene and naphthalene, and the like. Examples of the heteroaryl ring include thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine,

1.2. 4-oxadiazole, 1, 3, 4-oxadiazole, 1, 2, 4-thiadiazole, 1, 3, 4- thiadiazole, triazole, tetrazole, triazine and the like; and 8- to 14-membered fused polycyclic (preferably bi or tricyclic) aromatic heterocycles such as benzothiophene, benzofuran, benzimidazole, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzotriazole, imidazopyridine, thienopyridine, furopyridine, pyrrolopyridine, pyrazolopyridine, oxazolopyridine, thiazolopyridine, imidazopyrazine, imidazopyrimidine, thienopyrimidine, f uropyrimidine, pyrrolopyrimidine, pyrazolopyrimidine, oxazolopyrimidine, thiazolopyrimidine, pyrazolopyrimidine, pyrazolotriazine, naphtho [2, 3-b] thiophene, phenoxathiin, indole, isoindole, lH-indazole, purine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, carbazole, β-carboline, phenant hr idine, acridine, phenazine, phenothiazine, phenoxazine, and the like.

In another embodiment of the formula (I) , R _1b is hydrogen.

In one embodiment of the formula (I) , R _1c is optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl.

Examples of optionally substituted cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and the like.

Examples of optionally substituted heterocycloalkyl include piperidyl, 4-morpholinyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolidinyl, 1, 3-dioxanyl, 1, 4-dioxanyl, tetrazolyl, and the like.

Examples of optionally substituted aryl and optionally substituted heteroaryl include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuryl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, f uropyridinyl , thienopyridinyl, pyrropyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridinyl and the like.

In another embodiment of the formula (I) , R _1c is optionally substituted cycloalkyl, optionally substituted heterocycloalkyl ( e . g . , acet ylpiper idiny 1 ) .

In further another embodiment of the formula (I) , R _1c is optionally substituted heterocycloalkyl (e.g. , acet ylpiper idinyl) .

In one embodiment of the formula (I) , R ₂ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl. Examples of optionally substituted alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert -butyl, pentyl, isopentyl, neopentyl, tert -pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methyl thiopropyl, methyl thiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl, guanidinomethyl, guanidinoethyl, guanidinopropyl and the like.

Examples of optionally substituted alkenyl group include ethenyl, allyl, 1 -propenyl, 2-methylallyl and the like.

Examples of optionally substituted alkynyl group include ethynyl, 1-propynyl, and the like.

Examples of the optionally substituted arylalkyl group include unsubstituted arylalkyl or arylalkyl having an alkyl group such as benzyl, α-methylbenzyl, phenethyl, α- methylphenethyl, α , α-dimethylbenzyl, α , α-dimethylphenethyl, 4- methylphenethyl, 4 -methylbenzyl, 4 -isopropylbenzyl and the like; arylalkyl having an aryl group or an arylalkyl group such as 4- benzylbenzyl, 4 -phenethylbenzyl, 4 -phenylbenzyl and the like; arylalkyl having a substituted oxy group such as 4 -methoxybenzyl, 4-n-tetradecyloxybenzyl, 4-n-heptadecyloxybenzyl, 3, 4- dimethoxybenzyl, 4 -methoxymethylbenzyl, 4-vinyloxymethylbenzyl, 4 -benzyloxybenzyl, 4 -phenethyloxybenzyl and the like; arylalkyl having a hydroxyl group such as 4 -hydroxyphenethyl, 4- hydroxybenzyl, 4-hydroxy-3-methoxybenzyl and the like; arylalkyl having a halogen atom such as 4-fluorobenzyl, 3-chlorobenzyl, 3, 4 -dichlorobenzyl and the like; diphenylmethyl, diphenylpropyl, 1-naphthylmethyl, 2 -naphthylmethyl and the like.

Examples of the optionally substituted heteroarylalkyl group include 2-furfuryl, 2-benzodioxolylmethyl, 3- benzodioxolylmethyl, 2 -thienylmethyl, 3-thienylmethyl, 2- pyridylmethyl, 3-pyridylmethyl, 2-pyrimidinylmethyl, 5- pyrimidinylmethyl, 3-pyridazinylmethyl, 2-indolylmethyl, 5- indolylmethyl, 2 -benzof uranylmethyl, 5-indolylmethyl, 2- benzothienylmethyl , 5-benzothienylmethyl, 6-fluoro-2- benzof uranylmethyl , 6-chloro-2-benzof uranylmethyl, 6-;methoxy-2- benzof uranylmethyl , 6-fluoro-2-benzothienylmethyl, 6-chloro-2- benzothienylmethyl , 6-methoxy-2 -benzothienylmethyl , 6-phenyl-3- pyridazinylmethyl and the like.

Examples of the optionally substituted cycloalkylalkyl group include cyclopropylmethyl, fluorocyclopropylmethyl, chlorocyclopropylmethyl , bromocyclopropylmethyl , iodocyclopropylmethyl, methylcyclopropylmethyl, 1, 1- dimethylcyclopropylmethyl , 1 , 2 -dimethylcyclopropylmethyl , hydroxycyclopropylmethyl , methoxycyclopropylmethyl , ethoxycyclopropylmethyl , methpxycarbonylcyclopropylmethyl , methylcarbamoylcyclopropylmethyl , cyclopropylethyl , cyclohexylmethyl, cyclopropylhexyl and the like.

Examples of the optionally substituted heterocycloalkylalkyl group include (2 -tetrahydrofuryl) methyl, (2-tetrahydrothiof uranyl) methyl and the like.

In another embodiment of the formula (I) , R ₂ is hydrogen, optionally substituted alkyl (e.g. , methyl, isopropyl, isobutyl, -CH ₂ CH ₂ COOH) , optionally substituted arylalkyl (e.g. , benzyl, hydroxybenzyl) , optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl.

In further another embodiment of the f ormula ( I ) , R ₂ is optionally substituted alkyl (e. g. , methyl, isopropyl, isobutyl, -CH ₂ CH ₂ COOH) , or optionally substituted arylalkyl (e.g. , benzyl, hydroxybenzyl) .

In one embodiment of the formula (I) , m is 1 or 0.

In another embodiment of the formula (I) , m is 1.

In one embodiment of the formula (I) , L is -CH (R _9a ) - when m is 1, or -CH (R _9a ) -CH (Rgt>) - when m is 0.

R _9a and R _9b are independently hydrogen or optional substituted alkyl (e. g. , methyl) , preferably both are hydrogen atoms .

In one embodiment of the f ormula ( I ) , R ₃ is -W ₃₁ -W ₃₂ -R ₃₃ wherein W ₃₁ is - (CO) -, - (SO ₂ ) -, or -CH ₂ - W ₃₂ is — O— , -NH-, or single bond, and R ₃₃ is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl.

Examples of optionally substituted alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert -butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methylthiopropyl , methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl, guanidinomethyl, guanidinoethyl, guanidinopropyl and the like.

Examples of optionally substituted aryl and optionally substituted heteroaryl include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyr idopyr imidinyl , pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuryl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, f uropyr idinyl , thienopyridinyl, pyrropyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridinyl and the like.

Examples of optionally substituted cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamant yl and the like.

Examples of optionally substituted heterocycloalkyl include piperidyl, 4-morpholinyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolidinyl, 1, 3-dioxanyl, 1, 4-dioxanyl, tetrazolyl, and the like. Examples of the optionally substituted arylalkyl group include unsubstituted arylalkyl or arylalkyl having an alkyl group such as benzyl, α-methylbenzyl, phenethyl, α- methylphenethyl , α , α-dimethylbenzyl, α , α-dimethylphenethyl, 4- methylphenethyl , 4 -methylbenzyl, 4-isopropylbenzyl and the like; arylalkyl having an aryl group or an arylalkyl group such as 4- benzylbenzyl, 4 -phenethylbenzyl, 4 -phenylbenzyl and the like; arylalkyl having a substituted oxy group such as 4 -methoxybenzyl,

4 -n- tetradecyloxybenzyl, 4-n-heptadecyloxybenzyl, 3, 4- dimethoxybenzyl, 4 -methoxymethylbenzyl, 4-vinyloxymethylbenzyl, 4 -benzyloxybenzyl, 4 -phenethyloxybenzyl and the like; arylalkyl having a hydroxyl group such as 4 -hydroxyphenethyl, 4- hydroxybenzyl, 4-hydroxy-3-methoxybenzyl and the like; arylalkyl having a halogen atom such as 4-fluorobenzyl, 3-chlorobenzyl, 3, 4 -dichlorobenzyl and the like; diphenylmethyl, diphenylpropyl, 1 -naphthylmethyl, 2 -naphthylmethyl and the like.

Examples of the optionally substituted heteroarylalkyl group include 2-fur furyl, 2 -benzodi oxolylmethyl, 3- benzodioxolylmethyl, 2 -thienylmethyl, 3-thienylmethyl, 2- pyridylmethyl, 3-pyridylmethyl, 2-pyrimidinylmethyl, 5- pyrimidinylmethyl, 3-pyridazinylmethyl, 2-indolylmethyl, 5- indolylmethyl, 2 -benzof uranylmethyl, 5-indolylmethyl, 2- benzothienylmethyl , 5-benzothienylmethyl, 6-fluoro-2- benzof uranylmethyl , 6-chloro-2 -benzof uranylmethyl, 6-methoxy-2- benzof uranylmethyl , 6-f luoro-2-benzothienylmethyl , 6-chloro-2- benzothienylmethyl , 6-methoxy-2-benzothienylmethyl, 6-phenyl-3- pyridazinylmethyl and the like.

Examples of the optionally substituted cycloalkylalkyl group include cyclopropylmethyl, fluorocyclopropylmethyl, chlorocyclopropylmethyl , bromocyclopropylmethyl , iodocyclopropylmethyl, methylcyclopropylmethyl, 1, 1- dimethylcyclopropylmethyl , 1 , 2 -dimethyl cyclopropylmethyl , hydroxycyclopropylmethyl , methoxycyclopropylmethyl , ethoxycyclopropylmethyl , methoxycarbonylcyclopropylmethyl , methylcarbamoylcyclopropylmethyl , cyclopropylethyl , cyclohexylmethyl, cyclopropylhexyl and the like. Examples of the optionally substituted heterocycloalkylalkyl group include (2 -tetrahydrofuryl) methyl, (2-tetrahydrothiof uranyl) methyl and the like.

In another embodiment of the formula (I) , R ₃ is -W _31' -W _32' - R _33' wherein W _31' is - (CO) -, - (SO ₂ ) -, or -CH ₂ -, W _32' is -O-, -NH-, or single bond, and R _33' is optionally substituted alkyl (e.g. , isobutyl) , optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl (e.g. , benzyl, naphthylmethyl, diphenylpropyl, methylbenzyl, hydroxyphenethyl) , optionally substituted heteroarylalkyl (e.g. , pyridylmethyl, thienylmethyl, benzodioxolylmehtyl) , optionally substituted cycloalkylalkyl (e. g. , cyclohexylmethyl) , or optionally substituted heterocycloalkylalkyl .

In further another embodiment of the formula (I) , R ₃ is - W _{31' '} — W _{32' '} — R _{33' '} wherein W _31" is - (CO) -, or - (SO ₂ ) -, W _32' is -O-, -NH-, or single bond, and R _33' is optionally substituted alkyl (e.g. , isobutyl) , optionally substituted arylalkyl (e.g. , benzyl, naphthylmethyl, diphenylpropyl, methylbenzyl, hydroxyphenethyl) , optionally substituted heteroarylalkyl (e.g. , pyridylmethyl, thienylmethyl, benzodioxolylmehtyl) , or optionally substituted cycloalkylalkyl (e.g. , cyclohexylmethyl ) .

In one embodiment of the f ormula ( I ) , is represented by any of the following formulas (1-3) to

(1-4) :

In one embodiment of the formula (I) , R _4a is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl .

Examples of optionally substituted alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methyl thiopropyl , methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl, guanidinomethyl , guanidinoethyl, guanidinopropyl and the like.

Examples of optionally substituted alkenyl group include ethenyl, allyl, 1 -propenyl, 2-methylallyl and the like.

Examples of optionally substituted alkynyl group include ethynyl, 1-propynyl, and the like.

Examples of the optionally substituted arylalkyl group include unsubstituted arylalkyl or arylalkyl having an alkyl group such as benzyl, α-methylbenzyl, phenethyl, α- methylphenethyl, α , α-dimethylbenzyl, α , α-dimethylphenethyl, 4- methylphenethyl , 4 -methylbenzyl, 4-isopropylbenzyl and the like; arylalkyl having an aryl group or an arylalkyl group such as 4- benzylbenzyl, 4 -phenethylbenzyl, 4 -phenylbenzyl and the like; arylalkyl having a substituted oxy group such as 4 -methoxybenzyl, 4-n-tetradecyloxybenzyl, 4-n-heptadecyloxybenzyl, 3, 4- dimethoxybenzyl, 4 -methoxymethylbenzyl, 4-vinyloxymethylbenzyl, 4 -benzyloxybenzyl, 4 -phenethyl oxybenzyl and the like; arylalkyl having a hydroxyl group such as 4 -hydroxyphenethyl, 4- hydroxybenzyl, 4-hydroxy-3-methoxybenzyl and the like; arylalkyl having a halogen atom such as 4-fluorobenzyl, 3-chlorobenzyl, 3, 4 -dichlorobenzyl and the like; diphenylmethyl, diphenylpropyl, 1 -naphthylmethyl, 2 -naphthylmethyl and the like.

Examples of . the optionally substituted heteroarylalkyl group include 2-furfuryl, 2-benzodioxolylmethyl, 3- benzodioxolylmethyl, 2 -thienylmethyl, 3-thienylmethyl, 2- pyridylmethyl, 3-pyridylmethyl, 2-pyrimidinylmethyl, 5- pyrimidinylmethyl, 3-pyridazinylmethyl, 2-indolylmethyl, 5- indolylmethyl, 2 -benzof uranylmethyl, 5-indolylmethyl, 2- benzothienylmethyl , 5-benzothienylmethyl, 6-fluoro-2- benzof uranylmethyl , 6-chloro-2-benzof uranylmethyl, 6-methoxy-2- benzof uranylmethyl , 6- f luoro-2 -benzothienylmethyl , 6-chloro-2 - benzothienylmethyl , 6-methoxy-2-benzothienylmethyl , 6-phenyl-3- pyridazinylmethyl and the like.

Examples of the optionally substituted cycloalkylalkyl group include cyclopropylmethyl, fluorocyclopropylmethyl, chlorocyclopropylmethyl, bromocyclopropylmethyl, iodocyclopropylmethyl, methylcyclopropylmethyl, 1, 1- dimethylcyclopropylmethyl , 1, 2 -dimethylcyclopropylmethyl , hydroxycyclopropylmethyl , methoxycyclopropylmethyl , ethoxycyclopropylmethyl , methoxycarbonylcyclopropylmethyl , methylcarbamoylcyclopropylmethyl, cyclopropylethyl, cyclohexylmethyl, cyclopropylhexyl and the like.

Examples of the optionally substituted heterocycloalkylalkyl group include (2-tetrahydrofuryl) methyl, (2-tetrahydrothiof uranyl) methyl and the like.

In another embodiment of the formula (I) , R _4a is hydrogen, optionally substituted alkyl (e.g. , methyl, -CH ₂ CH ₂ CONH ₂ ) , optionally substituted arylalkyl (e. g. , benzyl) , optionally substituted cycloalkylalkyl.

In further another embodiment of the formula (I) , R _4a is hydrogen, optionally substituted alkyl (e.g. , methyl, - CH ₂ CH ₂ CONH ₂ ) , or optionally substituted arylalkyl (e.g. , benzyl) . In one. embodiment of the formula (I) , R _4b is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl.

Examples of optionally substituted alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert -butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, . methyl thioethyl, methyl thiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl, guanidinomethyl, guanidinoethyl, guanidinopropyl and the like.

Examples of optionally substituted alkenyl group include ethenyl, allyl, 1 -propenyl, 2 -methylallyl and the like.

Examples of optionally substituted alkynyl group include ethynyl, 1-propynyl, and the like.

Examples of the optionally substituted arylalkyl group include unsubstituted arylalkyl or. arylalkyl having an alkyl group such as benzyl, α-methylbenzyl, phenethyl, α- methylphenethyl, α , α-dimethylbenzyl, α , α-dimethylphenethyl, 4- methylphenethyl, 4 -methylbenzyl, 4-isopropylbenzyl and the like; arylalkyl having an aryl group or an arylalkyl group such as 4- benzylbenzyl, 4 -phenethylbenzyl, 4 -phenylbenzyl and the like; arylalkyl having a substituted oxy group such as 4 -methoxybenzyl, 4-n-tetradecyloxybenzyl, 4-n-heptadecyloxybenzyl, 3, 4- dimethoxybenzyl, 4 -methoxymethylbenzyl, 4-vinyloxymethylbenzyl, 4 -benzyloxybenzyl, 4 -phenethyloxybenzyl and the like; arylalkyl having a hydroxyl group such as 4 -hydroxyphenethyl, 4- hydroxybenzyl, 4-hydroxy-3-methoxybenzyl and the like; arylalkyl having a halogen atom such as 4-fluorobenzyl, 3-chlorobenzyl, 3, 4 -di chlorobenzyl and the like; diphenylmethyl, diphenylpropyl, 1 -naphthylmethyl, 2 -naphthylmethyl and the like. Examples of the optionally substituted heteroarylalkyl group include 2-furfuryl, 2-benzodioxo.lylmethyl, 3- benzodioxolylmethyl, 2 -thienylmethyl, 3-thienylmethyl, 2- pyridylmethyl, 3 -pyridylmethyl, 2-pyrimidinylmethyl, 5- pyrimidinylmethyl, 3-pyridazinylmethyl, 2-indolylmethyl, 5- indolylmethyl, 2 -benzof uranylmethyl, 5-indolylmethyl, 2- benzothienylmethyl , 5-benzothienylmethyl, 6-fluoro-2- benzof uranylmethyl , 6-chloro-2-benzof uranylmethyl, 6-methoxy-2- benzof uranylmethyl , 6- f luoro-2 -benzothienylmethyl , 6-chloro-2 - benzothienylmethyl , 6-methoxy-2-benzothienylmethyl , 6-phenyl-3- pyridazinylmethyl and the like.

Examples of the optionally substituted cycloalkylalkyl group include cyclopropylmethyl, fluorocyclopropylmethyl, chlorocyclopropylmethyl , bromocyclopropylmethyl , iodocyclopropylmethyl, methylcyclopropylmethyl, 1, 1- dimethylcyclopropylmethyl , 1 , 2 -dimethyl cyclopropylmethyl , hydroxycyclopropylmethyl , methoxycyclopropylmethyl , ethoxycyclopropylmethyl , methoxycarbonylcyclopropylmethyl , methylcarbamoylcyclopropylmethyl , cyclopropylethyl , cyclohexylmethyl, cyclopropylhexyl and the like.

Examples of the optionally substituted heterocycloalkylalkyl group include (2-tetrahydrofuryl) methyl, (2-tetrahydrothiof uranyl) methyl and the like. In another embodiment of the formula (I) , R _4b is hydrogen or optionally substituted alkyl (e. g. , methyl) .

In another embodiment of the formula (I) , R _4a and R _4b may form a spiro ring together with a carbon bonded thereto. The spiro ring that may be formed by R _4a and R _4b together with a carbon bonded thereto is, for example, cyclopropane, cyclobutane or the like.

The spiro ring may contain oxygen atom or nitrogen atom in the ring.

In one embodiment of the. formula (±) , A is -CH (R ₅ ) -, - N (R ₅ ) -, -O- or single bond.

In one embodiment of the formula (I) , R ₅ is hydrogen or optionally substituted alkyl . Examples of optionally substituted alkyl group include methyl, ethyl, propyl, . isopropyl, butyl, isobutyl, sec-butyl, tert -butyl, pentyl, isopentyl, neopentyl, tert -pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methyl thiomethyl, methyl thioethyl, methyl thiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl, guanidinomethyl, guanidinoethyl, guanidinopropyl and the like..

In another embodiment of the formula (I) ,. R ₅ is hydrogen. In another embodiment of the formula (I) , A is -CH ₂ - or -

O- .

In one embodiment of the formula (I) , ring B is an optionally substituted aryl ring, an optionally substituted heteroaryl ring, an optionally substituted cycloalkyl ring or an optionally substituted heterocycloalkyl ring.

Examples of the aryl ring include benzene and naphthalene, and the like. Examples of the heteroaryl ring include thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, 1, 2, 4 -oxadiazole, 1, 3, 4-oxadiazole, 1, 2, 4-thiadiazole, 1, 3, 4- thiadiazole, triazole, tetrazole, triazine and the like; and 8- to 14-membered fused polycyclic (preferably bi or tricyclic) aromatic heterocycles such as benzothiophene, benzofuran, benzimidazole, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzotriazole, imidazopyridine, thienopyridine, furopyridine, pyrrolopyridine, pyrazolopyridine, oxazolopyridine, thiazolopyridine, imidazopyrazine, imidazopyrimidine, thienopyrimidine, f uropyrimidine, pyrrolopyrimidine, pyrazolopyrimidine, oxa zolopyrimi dine, thia zolopyrimi dine, pyrazolopyrimidine, pyrazolotriazine, naphtho [2, 3-b] thiophene, phenoxathiin, indole, isoindole, lH-indazole, purine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, carbazole, β-carboline, phenanthridine, acridine, phenazine, phenothiazine, phenoxazine, and the like.

Example of the cycloalkyl ring include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, and the like.

Example of the heterocycloalkyl ring include pyrrolidine, piperidine, morpholine, piperazine, 1, 3-dioxane, 1, 4-dioxane, and the like.

In another embodiment of the formula (I) , ring B is an optionally substituted heteroaryl ring (e. g. , thiophen) .

In one embodiment of the compound represented by the formula ( I ) , A is -CH ₂ - or -O-; ring B is an optionally substituted aryl ring or an optionally substituted heteroaryl ring; m is 1;

L is -CH (R _9a ) -;

R _9a is hydrogen or methyl; R _1a is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl;

R _1b is hydrogen;

R _1c is optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;

R ₂ is hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl or optionally substituted cycloalkylalkyl;

R _4a is hydrogen, optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted cycloalkylalkyl; R _4b is hydrogen or optionally substituted alkyl; and

R _4a and R _4b optionally form a spiro ring together with a carbon bonded thereto, which optionally has oxygen atom or nitrogen atom in the ring. In another embodiment of the compound represented by the formula ( I ) ,

A is -CH ₂ - or -O-; ring B is an optionally substituted aryl ring or an optionally substituted heteroaryl ring; m is 0;

L is -CH (R _9a ) -CH (R _9b ) -;

R _9a and R _9b are independently hydrogen or methyl; R _1a is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl;

R _1b is hydrogen;

R _1c is optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;

R ₂ is hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl or optionally substituted cycloalkylalkyl;

R _4a is hydrogen, optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted cycloalkylalkyl;

R _4b is hydrogen or optionally substituted alkyl; and

R _4a and R _4b optionally form a spiro ring together with a carbon bonded thereto,, which optionally has oxygen atom or nitrogen atom in the ring.

In further another embodiment of the compound represented by the formula ( I ) , A is -CH ₂ - or -O-; ring B is an optionally substituted heteroaryl ring; m is 1;

L is -CH (R _9a ) -;

R _9a is hydrogen; R _1a is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted arylalkyl;

R _1b is hydrogen;

R _1c is optionally substituted heterocycloalkyl; R ₂ is hydrogen, optionally substituted alkyl, or optionally substituted arylalkyl;

R ₃ is — W _31" — W _32" — R _33" wherein

W _31" is - (CO) -, or - (SO ₂ ) -,

W _32' is -O-, -NH-, or single bond, and

R _33' is optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl,

R _4a is hydrogen, optionally substituted alkyl, or optionally substituted arylalkyl;

R _4a is hydrogen, optionally substituted alkyl; and

R _4a and R _4b optionally form a spiro ring together with a carbon bonded thereto, which optionally has oxygen atom or nitrogen atom in the ring.

In the following, a compound having the formula (I) is to be also referred to as "the compound of the present invention" .

The general synthesis of the compound of the present invention is described in the following "Production Method". Abbreviations used in the Production Method and Examples are as follows . AcOH: acetic acid • ACONH ₄ : ammonium acetate Boc : tert -butoxycarbonyl t-BuOH: tert -butanol Cbz : benzyloxycarbonyl CDCI ₃ : deuterated chloroform CIP: 2-chloro-l, 3-dimethylimidazolinium hexafluorophosphate DBU: 1, .8 -diazabicyclo [5. 4.0] undec-7-ene DCE: 1 2 -dichloroethane DCM: dichloromethane

DIAD: diisopropyl azodicarboxylate

DIBAL: diisobutylaluminium

DIC : N, N ' -methanediylidenebis [ 1-methylethanamine]

DIEA: N,N-diisopropylethylamine

DIPEA : N -ethyl -N- i sopr opy 1 -propan- 2 -amine DMF: N,N-dimethyl formamide DMSO: dimethyl sulfoxide

DMT -MM: 4- (4, 6-dimethoxy-l, 3, 5-triazin-2-yl) -4- methylmorpholinium chloride EtO (OEt) : ethoxy EtOAc (AcOEt) : ethyl acetate EtOH : ethanol Fmoc : 9-f luorenylmethyloxycarbonyl

HATU: 1- [bis (dimethylamino) methylene] -1H-1, 2, 3-triazolo [4, 5- b] pyridinium 3-oxide hexafluorophosphate

HBTU : 1- [bis (dimethylamino) methylene] -lH-benzotriazolium 3-oxide hexafluorophosphate MeCN: acetonitrile MeO (OMe) : methoxy MeOH : methanol

NHPI : N-Hydroxyphthalimide NMM: N-methylmorpholine NEta : triethylamine OAc (AcO) : acetoxy Pbf : 2, 2, 4, 6, 7-Pentamethyldihydrobenzofuran-5-sulfonyl PE:EA: Petroleum ether: Ethyl acetate PG: amino-protecting group Ph : phenyl PhthN : N-Phthalimidyl PPh3 : triphenylphosphine rt : room temperature

TBS: tert -butyldimethylsilyl

TBSC1 : tert-Butyl (chloro) dimethylsilane

TBTU : 1- [Bis (dimethylamino) methylene] -lH-benzotriazolium 3-0xide Tetrafluoroborate tBu: tert -butyl

TFA: trifluoroacetic acid THF: tetrahydrofuran

TLC: Thin-layer chromatography

Trt: trityl

TsCl: tosyl chloride

Production Method 1) Production Method 1

[Step 1] Synthesis of Intermediate A

[ Intermediate A] (wherein L and R ₁ are as defined above) can be synthesized according to a known method such as reductive alkylation using a compound represented by the formula [Int-a] (wherein L is as defined above) , and an aldehyde compound represented by the formula. [Int-b] (wherein R _1a and R _1b are as defined above) , or a substitution reaction using a compound represented by the formula [Int-c] (wherein X is a leaving group and Ri is as defined above) . The "leaving group" means an atom or an atomic group that is released from an organic compound that undergoes a reaction in an elimination reaction or substitution reaction. Examples of the leaving group include, but are not limited to, halogen atoms, methanesulfonyloxy group, trifluoromethanesulfonyloxy group and toluenesulfonyloxy group.

In addition, [Intermediate A] can also be synthesized by known methods such as reductive alkylation or substitution reaction using a leaving group X as shown below.

In each of the formulas of the compounds represented by the formulas [Int-dl] , [Int-d2] , [Int-e] and [Int-f] , X is a leaving group, and R ₁ , R _9a , R _9b and L are as defined above.

[Step 2] Synthesis of Intermediate C

Intermediate C can be synthesized by an amidation condensation reaction of [Intermediate A] and a carboxylic acid derivative [Intermediate B] (wherein R ₂ and m are as defined above, and PGi is an amino-protecting group) , followed by a deprotection reaction. In the amidation condensation reaction, generally known amidation reagents and conditions can be applied. HATU, HBTU and DMT -MM are preferable as the condensing agent,. DMF, MeOH, THF and the like are preferable as the solvent, and the reaction temperature is preferably from 0°C to the boiling point of the solvent. Examples of the amino-protecting group PGi include benzyloxycarbonyl (Cbz) , tert-butoxycarbonyl (Boc) , tert -pentyloxycarbonyl, isobornyloxycarbonyl, 4- methoxybenzyloxycarbonyl, benzyl chloroformate (Cl-Z) , benzyl bromoformate (Br-Z) , adamant yloxycarbonyl, trifluoroacetyl, phthaloyl, formyl, 2-nitrophenylsulphenyl, diphenylphosphinothioyl, 9-fluorenylmethyloxycarbonyl (Fmoc) , trityl (Trt) and the like. In the deprotection reaction, a generally known reaction can be applied. When PGi in the formula is an Fmoc group, a deprotection reaction using piperidine or DBU as a deprotecting agent in ethyl acetate, THF, MeOH or dichloromethane as a solvent is preferable. When PGi is a Cbz group, a deprotection reaction using a palladium catalyst such as Pd (OH) ₂ , Pd/C or the like in methanol, ethanol or THF as a solvent under H ₂ atmosphere is preferable. The reaction temperature is preferably 0°C to the boiling point of the solvent .

[Step 3] Synthesis of compound (I)

Compound (I) (wherein symbols in the formula are as defined above) can be synthesized by an amidation condensation reaction of [Intermediate C] and [Intermediate D] (Rs and W are as defined above) , followed by a ring closure reaction in the presence of an acid. In the amidation condensation reaction, generally known amidation reagents and conditions can be applied. HATU, HBTU or DMT -MM is preferable as the condensing agent, DMF, MeOH, THF or the like is preferable as the solvent, and the reaction temperature is preferably 0°C to the boiling point of the solvent. As the acid to be used for the ring closure reaction, formic acid is preferable and formic acid can also be used as the solvent.

2) Production Method 2 [Int-g] (wherein symbols in the formula are as defined above) can be synthesized by an amidation condensation reaction of [Intermediate C] and [Intermediate D] (wherein symbols in the formula are as defined above) , followed by a ring closure reaction in the presence of an acid as described in Step 3 described in the Production Method 1. Deprotection of the tertbutyl ester also proceeds in the presence of acid. In the ring closure reaction, the t-Butyl ester group is deprotected and converted to a carboxylic acid in the presence of acid.

Compound (I) (wherein symbols in the formula are as defined above) can be synthesized by an amidation condensation reaction of [Int-g] and [Int-h] (wherein R ₁₃ is as defined above) . In the amidation condensation reaction, generally known amidation reagents and conditions can be applied. HATU, HBTU or DMT -MM is preferable as the condensing agent, DMF, MeOH, THF or the like is preferable as the solvent, and the reaction temperature is preferably 0°C to the boiling point of the solvent . The reaction temperature is preferably 0°C to the boiling point of the used solvent.

3) Production Method 3

Compound (I) wherein R ₃ is - (CO) -NH-Ra3 can be synthesized by deprotection reaction of Intermediate [Int-i] (PG2 is an amino-protecting group, other symbols in the formula are as defined above) followed by the condensation reaction with an amine derivative R ₃₃ -NH ₂ using triphosgene. [Int-i] can be prepared by generally known methods, or the Step 1, Step 2 and Step 3 described in the Production Method 1.

Representative Examples of the amino-protecting group PG ₂ include benzyloxycarbonyl (Cbz) , 9-fluorenylmethyloxycarbonyl (Fmoc) and the like. In the deprotection reaction, a generally known reaction can be applied. When PG2 in the formula is an . Fmoc group, a deprotection reaction using piperidine or DBU as a deprotecting agent in ethyl acetate or dichloromethane as a solvent is preferable. When PG2 is a Cbz group, a deprotection reaction using a palladium catalyst such as Pd (OH) 2, Pd/C or the like in methanol, ethanol or THF as a solvent under H ₂ atmosphere is preferable. The reaction temperature is preferably 0°C to the boiling point of the used solvent , In the condensation reaction, DCM, DCE, THF or the like is a preferable solvent and the reaction temperature is preferably 0°C to the boiling point of the used solvent.

4) Production Method 4

Compound ( I ) wherein R ₃ is - (CO) -O-R ₃₃ can be synthesized by a reaction using the intermediate [Int-j ] , an alcohol derivative R ₃₃ -OH and triphosgene. DCM, DCE, THF or the like is a preferable solvent, and the reaction temperature is preferably 0°C to the boiling point of the used solvent.

5) Production Method 5

Compound (I) wherein R ₃ is - (CO)-R ₃₃ can be synthesized by an amidation condensation reaction using the intermediate [Int- j ] and R ₃₃ -COOH (or R ₃₃ -COCI) . DMF, DCM, DCE, THF, MeOH or the like is preferable as the solvent, and the reaction temperature is preferably 0°C to the boiling point of. the solvent. When R ₃₃ -

COOH is used, generally known amidation reagents such as HATU, CIP or DMT -MM are used as the condensing, agent.

6) Production Method 6

Compound (I) wherein R ₃ is - (SO ₂ ) -R ₃₃ can be synthesized by condensation reaction using the intermediate [Int-j ] and R ₃₃ - SO ₂ CI. DCM, DCE, THF or the like is a preferable solvent. The reaction temperature is preferably 0 °C to the boiling point of the used solvent.

The protecting group in each step is not limited to the protecting group (e. g. , a diethyl acetal group) specifically indicated in the scheme, and a generally-known protecting group such as a dimethylacetal group may be used. Deprotection in Step 2 in the Production Method 1 or in the Production Method 3 can be performed by a general method corresponding to the protecting group. When R ₁ , R _1a , R _1b , R _1c , R ₁₃ , R ₁₄ , R ₁₅ , R ₂ , R ₃ , R ₃₃ , R _4a , R ₅ , R _9a , R _9b or B has a protected functional group, deprotection can be performed in any step. The compound synthesized in each step of the reaction may be directly used in the next reaction without isolation. Under the conditions . of Step 3 in the Production Method 1, the ring closure reaction and the deprotection reaction may proceed simultaneously.

The compound to be obtained in the cyclization reaction etc. can be isolated and purified by a conventional method such as extraction, water-washing, acid washing, alkali washing, crystallization, recrystallization, silica gel column chromatography . Explaining further, the compounds of the present invention, salts thereof and derivatives thereof are excellent in pharmacological action selectivity, safety (various toxicities and safety pharmacology) , pharmaco kinetic performance, physicochemical property and the like, and therefore the usefulness as active ingredients of medicaments can be confirmed. Examples of tests concerning pharmacological action selectivity include, but not be limited to, inhibition or activation assays on various pharmacological target receptors, inhibition assays on various pharmacological target enzymes, ion channels or transporters, cellular tests to be used for the evaluation for various pharmacological action, and the like.

Examples of tests concerning safety include, but not be limited to, the following list including cytotoxic tests (e.g. , tests using HL60 cells, hepatocytes, etc. , and the like) , genotoxicity tests (e.g. , Ames test, mouse lymphoma TK test, chromosomal aberration test, micronucleus test and the like) , skin sensitization tests (e.g. , Buehler method, GPMT method, APT method, LLNA test and the like) , skin photosensitization tests (e.g. , Adjuvant and Strip method and the like) , eye irritation tests (e.g. , single instillation, short-term continuation instillation, repetitive instillation and the like) , safety pharmacology tests for the cardiovascular system (e.g. , telemetry method, APD method, hERG inhibition assay and the like) , safety pharmacology tests for the central nervous system (e.g. , FOB method, modified version of Irwin method and the like) , safety pharmacology tests for the respiratory system (e.g. , measurement method using a respiratory function measuring apparatus, measurement method using a blood gas analyzer and the like) , general toxicity tests, and the like.

Examples of tests concerning pharmacokinetic performance include, but not be limited to, the following list including cytochrome P450 enzyme inhibition or induction tests, cell permeability tests (e. g. , tests using CaCO-2 cells, MDCK cells etc. , and the like) , drug transporter ATPase assay, oral absorption tests, blood concentration transition measurement tests, metabolism tests (e.g. , stability test, metabolite molecular species test, reactivity test and the like) , solubility tests (e.g. , solubility test based on turbidity method and the like) , and the like.

Examples of tests concerning physicochemical property include, but not be limited to, the following list including chemical stability test (e. g. , stability test using HPLC etc. , and the like) , partition coefficient (e.g. , partition test using octanol phase/water phase and the like) , ionization constant test, crystallization test, and the like.

In another embodiment, a method for treating various diseases by administering the compound of the present invention is provided. The compound of the present invention may be used for preventing or treating diseases controlled by Notch signal transduction pathway.

In one embodiment, screening relating to the inhibitory action of the Notch signal transduction pathway is performed using a doxycycline-inducing lentiviral vector (see Examples for specific procedures) .

The test compound here is a compound described in the present specification, that is, the compound of the present invention. Typically, test compounds are tested at several different concentrations, and the. concentrations are partly selected according to the assay conditions .

The compound of the present invention may inhibit Notch signal transduction by interacting with the Notch intracellular domain .

The present invention is also related to prodrugs using the libraries containing one or more . compounds of the present invention. A prodrug is typically designed to release the active drug in the body during or after absorption by enzymatic and/or chemical hydrolysis. The prodrug approach is an effective means of improving the oral bioavailability or i.v. administration of poorly water-soluble drugs by chemical derivatization to more water-soluble compounds . The most commonly used prodrug approach for increasing aqueous solubility of drugs containing a hydroxyl group is to produce esters containing an ionizable group; e. g. , phosphate group, carboxylate group, alkylamino group (Fleisher et al. , Advanced Drug Delivery Reviews, 115-130, 1996; Davis et al. , Cancer Res. , 7247-7253) .

In other aspects, the present invention provides pharmaceutical compositions containing a compound of the present invention. These compositions may be used in various methods of the present invention as described in detail below.

The pharmaceutical composition of the present invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g. , intravenous, intradermal, subcutaneous, oral (e. g. , inhalation) , transdermal (topical) , transmucosal, and rectal administration. Solutions or suspensions (e. g. , injection) used for parenteral (particularly, intravenous) , intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. In addition, pH may be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile . aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS) . In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like) , and suitable mixtures thereof . The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants . Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.

Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound, e.g. , a compound having general formula (I) in the required amount, in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a. sterile vehicle that contains a dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously, sterile-filtered solution thereof .

Oral compositions generally include an inert diluent or an edible carrier. They, can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules.

Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser that contains a suitable propellant, e. g. , a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means . For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories . For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g. , with conventional, suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems . Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza.. Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in' U. S. Patent No. 4, 522, 811.

It can be advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a 5 predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

For instance, in certain embodiments, a pharmaceutical composition of the present . invention is one suitable for oral administration in unit dosage form such as a tablet or capsule that contains from about 1 mg to about 1 g of the compound of this invention. In some other embodiments, a pharmaceutical composition of the present invention is one suitable for intravenous, subcutaneous or intramuscular injection. A patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of about 1 μ g/kg to about lg/kg of the compound of the present invention. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection or by continuous infusion over a period of time. Alternatively a patient will receive a daily oral dose approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

Preferably, the compound of the formula (I) of the present invention can be administered intravenously (particularly preferably, by continuous drip- infusion or rapid intravenous administration) to mammals inclusive of human. In the case, the dose is selected appropriately depending on various factors such as the body weight and/or age of patients, and/or the degree of the symptom and an administration route. For example, the dose of the compound of the formula ' (I) for intravenous administration is generally in the range of 1 to 10000 mg/day/m ² human body surface area, preferably in the range of 1 to 5000 mg/day/m ² human body surface area, and more preferably 10 to 5000 mg/day/m ² human body surface area by continuous drip infusion administration.

A pharmaceutical composition containing the compound of the present invention can be used . for diseases regulated by Notch signal transduction pathway. More specifically, a compound that inhibits Notch signal provides a method for suppressing expression of Hesl and Hes5 and promoting differentiation of neural stem cells, and is expected to be a candidate for a new nerve regeneration drug.

The present invention also provides methods for promoting differentiation of a neural stem cell comprising contacting a neural stem cell with a compound according to formula (I) in an amount effective to promote differentiation of a neural stem cell. Such methods are also useful in treating neurodegenerative diseases (e.g. , glaucoma, macular degeneration, Parkinson' s Disease, and Alzheimer' s disease) and injuries to nervous system. "Neural stem cell" refers to a clonogenic, undifferentiated, multipotent cell capable of differentiating into a neuron, an astrocyte or an oligodendrocyte under appropriate conditions. A compound promotes differentiation of neural stem cells if neural stem cells exhibit a statistically significantly higher degree of differentiation in the presence of the compound than in the absence of the compound. Such a compound may be identified using assays involving in vitro cultured stem cells or animal models (Albranches et al . , Biotechnol. Lett. 25: 725-30, 2003; Deng et al. , Exp. Neurol. 182 : 373-82, 2003; Munoz-Elias et al. , Stem Cells 21: 437-48, 2003; Kudo et al, Biochem. Pharmacol. 66: 289- 95, 2003; Wan et al. , Chin. Med. J. 116: 428-31, 2003;

Kawamorita et al. , Hum. Cell 15: 178-82, 2002; Stavridis and Smith, Biochem. Soc. Trans. 31 : 45-9, 2003; Pachemik et al. , Reprod. Nutr. Dev. 42 : 317-26, 2002; Fukunaga et al. , supra) . The neural stem cell may be a cultured stem cell, a stem cell freshly isolated from its source tissue, or a stem cell within its source organism. Thus, contacting the neural stem cell with a compound according to the present invention may be carried out either in vitro (for a cultured or freshly isolated stem cell) or in vivo (for a stem cell within its source organism) . The resulting differentiated neural cell, if generated in vitro, may be transplanted into a tissue in need thereof (Lacza et al. , supra; Chu "et al. , supra; Fukunaga et al. , supra) . Such a. tissue includes a brain tissue or. other nervous tissue that suffers from a trauma or a neurodegenerative disease.

The following non-limiting examples illustrate the compounds, compositions, and methods of use of this invention.

[Examples]

The present invention is explained in more detail in the following by referring to Production Examples, Examples, Reference Examples and Experimental Examples; however, the scope of the present invention is not limited thereto.

In the Examples, ¹ H NMR was measured using Bruker AVANCE III 400; Bruker AVANCE III 400 HD and Bruker AVANCE NEO 40, or Bruker AVANCE III 300.

Preparative HPLC (prep-HPLC) was performed using GILSON- GX-28 or Waters FractionLynx system. Preparation conditions used are as follows .

General prep-HPLC condition (AcOH) :

Column: C30-UG 25mmID*150mmL, 5μm

Mobile phase A: water with 0.10% v/v acetic acid

Mobile phase B: acetonitrile

UV detection wavelength: 220nm

Flow rate: 25 ml /min

Temperature : room temperature

Gradient time table:

0 min B=x%, A=100-x%

0.01 - 10.99 min linear gradient

11.00 min B=y%, A=100-y%

11.01 - 11.20 min B=y%, A=100-y% 11.21 - 13.00. min B=100%

13.01 - 15.00 min B=z%, A=100-z% x, y and z values depend on the kind of compounds.

LCMS analysis was performed using the following Method A or B: (Method A)

System: Shimadzu UFLC/MS System (Shimazu-2020 mass spectrometer) Column: ODS column for the. chromatography column

Eluents: A (5 mM AcONH ₄ in water) and B (5 mM ACONH ₄ in acetonitrile) (Method B)

System: Shimadzu UFLC/MS System (Shimazu-2020 mass spectrometer) Column: ODS column for the chromatography column

Eluents: A (water with 0.04% TFA) and B (acetonitrile with 0.04% TFA)

Production Example 1 : Synthesis of Intermediate A-02

To . a solution of 2 -bromo- 1, 1-diethoxyethane (50 g, 0.69 . mol) in MeCN (0.7 L) was added potassium carbonate (94.5 g, 0.69 mol) and n-butylamine (50 g, 0.69 mol) . After refluxing • overnight, the mixture was filtered and evaporated. The residue was dissolved in ethyl acetate (1.0 L) , washed with water (0.5 L) and brine (0.5 L) , dried over sodium sulfate, filtered and evaporated. The target material A-02 (71 g, colorless oil, 55% yield) was obtained by the reduced-pressure distillation (70°C, 5-10 mmHg) .

¹ H NMR (400 MHz, CDCI ₃ ) data of . A-02 is shown in Fig. 1..

Production Example 2 : Synthesis of Intermediate A-03

To a solution of 2, 2-diethoxyethan-l-amine 75 g (0.67 mol) in MeOH (1.0 L) was added cyclohexanecarbaldehyde 89 g (0.67 mol) . After stirring overnight, the mixture was added sodium borohydride 38.2 g (1.0 mol) at 0 °C with stirring at room temperature for 1.5 hrs. The mixture was concentrated, and the residue was dissolved in ethyl acetate (1.0 L) , washed with water (1.0 L) and brine (1.0 L) , dried over sodium sulfate, filtered and evaporated. The target material A-03 (130 g, colorless oil, yield 85%) was obtained by the reduced-pressure distillation (140 °C, 5-10 mmHg) .

¹ H NMR (400 MHz, CDCI ₃ ) data of A-03 is shown in Fig. 2.

Production Example 3 : Synthesis of Intermediate A-09

To a solution of tert-butyl (4 -hydroxybutyl) carbamate (0.20 kg) in dichloromethane (1.5 L) was added triethylamine (0.21 kg) at 10 °C. Then methanesulfonyl chloride (0.16 kg) was added dropwise. After being stirred 1 h at 10 °C, the mixture was quenched with saturated sodium bicarbonate solution. The organic phase was washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated to give 4- ( (tert -but oxycarbonyl) amino) butyl methanesulfonate (0.25 kg) as a yellow oil. The product was used next step without further purification.

To a solution of 4- ( (tert -butoxycarbonyl) amino) butyl methanesulfonate (0.25 kg) in acetonitrile (2.0 L) was added 2, 2-diethoxyethanamine (0 ; 13 kg) and potassium carbonate (0.26 kg) . The mixture was heated to 60 °C and stirred overnight. The mixture was poured into water and extracted with ethyl acetate (1.0 L x 3) . .The organic, phase was washed with brine, dried over anhydrous sodium sulfate and concentrated to give the desired product (0.20 kg) as a yellow oil. The product was used next step without further purification.

Intermediates A-01 to A-12 were synthesized according to the same method as described above or a known method.

A list of Intermediate A is shown in the Table 1.

[Table 1] Intermediates B-01 to B-06 shown in Table 2 are commercially available or can be synthesized according to a known method. [Table 2]

Production Example 4 : Synthesis of Intermediate C-06

To a solution of (R) -3- ( ( ( (9H-fluoren-9- yl ) methoxy) carbonyl) amino) -2-methylpropanoic acid (30 g) in DMF (0.13 L) was added diisopropylethylamine (42 g) and TBTU (59 g) . The mixture was stirred 1 h at room temperature. Then N-

( cyclohexylmethyl) -2, 2 -diethoxyethanamine (25 g) was added. The mixture was stirred overnight . The mixture was poured into water and extracted with dichloromethane (0.20 L x 3) . The organic phase was dried over anhydrous Na ₂ SO ₄ and concentrated. The residue was purified by column on silica gel to give C-06-intl (37 g) as yellow oil.

To a solution of C-06-intl (37 g) in dichloromethane (0.35 L) was added piperidine (30 g) . The mixture was stirred overnight at room temperature. The mixture was poured into water and extracted with dichloromethane (0.10 L x 2) . The organic phase was dried over anhydrous Na ₂ SO ₄ and concentrated. The residue was purified by column on silica gel to give the desired product (10 g) as yellow oil. . LCMS (method A) : m/z = 315.2 [M+H] ⁺ .

Intermediates C-01 to C-27 in Table 3 (Table 3-1 to Table 3-4) were synthesized using Intermediate A and Intermediate B according to the same method as described above or a known method.

[Table 3-1]

[Table 3-2]

[Table 3-3]

[Table 3-4]

Intermediates D-01 to D-27 in Table 4 (Table 4-1 to Table 4-2) were synthesized according to a known method, for examples, methods described in WO2010/128685.

[Table 4-1]

[Table 4-2]

Example 1: Synthesis of ID-39

To a solution of C-23 (24 mg) , D-20 (25 mg) in methanol (0.6 mL) was added 4- (4, 6-dimethoxy-l, 3, 5-triazin-2-yl) -4- methylmorpholinium chloride n-hydrate (DMT-MM) (24 mg) . The mixture stood 1 hour at room temperature. The reaction mixture was diluted with AcOEt (5 mL) and washed with saturated sodium hydrogen carbonate solution (1 mL) , water (1 mL) , dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (SiO ₂ , n-Hexane : AcOEt = 50: 50-0: 100, gradient) to give ID-39-intl (43 mg) as colorless oil.

LCMS (method B) : m/z = 674.4 [M+H] ⁺ , 696.4 [M+Na] ⁺ .

ID-39-intl (43 mg) was dissolved in formic acid (1 mL) and stirred for 18 days at 40 °C and 3 days at 50 °C. The mixture was concentrated under reduced pressure and the residue was purified by prep-HPLC to give the product ID-39 (5.1 mg) as white solid.

LCMS (method B) : m/z = 526.3 [M+H] ⁺ .

¹ H NMR (400 MHz, CDCl ₃ ) data of ID-39 is shown in Fig. 3.

Compounds ID-01 to ID-45 in Table 5 (Table 5-1 to Table 5- 7) can be synthesized using Intermediate C and Intermediate D according to the same method . as described above or a known method. [Table 5-1]

[Table 5-2]

[Table 5-3]

[Table 5-4]

[Table 5-5]

[Table 5-6]

[Table 5-7]

In the compounds ID-01, 04, 06 to 14, 20, 22, 27, 31 to 38, 42 and 45, diastereomeric mixtures are separately observed by LCMS analysis .

Chemical names of compounds ID-01 to ID-45 are listed as below: ID-01

(7R) -N-benzyl-7-isopropyl-9- (naphthalen-2-ylmethyl) -4, 8- dioxooctahydropyrimido [1, 2-a] [1, 4] diazepine-1 (2H) -carboxamide ID-02

(7R) -9-butyl-7-isobutyl-4, 8-dioxo-N- (pyridin-4- ylmethyl) octahydropyrimido [1, 2-a] [1, 4] diazepine-1 (2H) - carboxamide ID-03

(7R) -9- (cyclohexylmethyl) -7-methyl-N- (naphthalen-1- ylmethyl) -4, 8-dioxooctahydropyrimido [1, 2-a] [1, 4] diazepine-1 (2H) - carboxamide

ID-04

(7R) -7-benzyl-9-butyl-N- (3, 3 -diphenylpropyl) -4, 8- dioxooctahydropyrimido [ 1 , 2-a] [1, 4] diazepine-1 ( 2H) -carboxamide ID-05

(7R) -N- (3, 3 -diphenylpropyl) -7- (4 -hydroxybenzyl) -9- isopentyl-4, 8-dioxooctahydropyrimido [1, 2-a] [1, 4] diazepine-1 (2H) - carboxamide

ID-06 (7R) -7-benzyl-N- (3, 3 -diphenylpropyl) -9-isopentyl-4, 8- dioxooctahydropyrimido [1, 2-a] [1, 4] diazepine-1 (2H) -carboxamide ID-07

(7R) -7-benzyl-9- (cyclohexylmethyl) -N- (3, 3 -diphenylpropyl) - 4, 8-dioxooctahydropyrimido [1, 2-a] [1, 4] diazepine-1 (2H) - carboxamide

ID-08

(7R) -7, 9-dibenzyl-N- (3, 3 -diphenylpropyl) -4, 8- dioxooctahydropyrimido [1, 2-a] [1, 4] diazepine-1 (2H) -carboxamide ID-09

(7R) -N- (3, 3 -diphenylpropyl) -7-isopropyl-4, 8-dioxo-9- phenethyloctahydropyrimido [1, 2-a] [1, 4] diazepine-1 (2H) - carboxamide ID-10

(7R) -N- (3, 3 -diphenylpropyl) -7-isobutyl-4, 8-dioxo-9- phenethyloctahydropyrimido [1, 2-a] [1, 4] diazepine-1 (2H) - carboxamide

ID-11

(7R) -N- (3, 3 -diphenylpropyl) -7- (4 -hydroxybenzyl) -4, 8-dioxo- 9-phenethyloctahydropyrimido [1, 2-a] [1, 4] diazepine-1 (2H) - carboxamide

ID-12

(7R) -7-benzyl-N- (3, 3 -diphenylpropyl) -4, 8-dioxo-9- phenethyloctahydropyrimido [1, 2-a] [1, 4] diazepine-1 (2H) - carboxamide ID-13

(7R) -N- (3, 3 -diphenylpropyl) -7- (4 -hydroxybenzyl) -4, 8-dioxo- 9- (quinolin-8-ylmethyl) octahydropyrimido [1, 2-a] [1, 4] diazepine- 1 (2H) -carboxamide ID-14

(7R) -N- (3, 3-diphenylpropyl) -7-isopropyl-9- (naphthalen-2- ylmethyl) -4, 8-dioxooctahydropyrimido [1, 2-a] [1, 4] diazepine-1 (2H) - carboxamide

ID-15

(7R) -N- (cyclohexylmethyl) -7- (4 -hydroxybenzyl) -9- (naphthalen-l-ylmethyl) -4, 8-dioxooctahydropyrimido [1, 2- a] [1, 4] diazepine-1 (2H) -carboxamide ID-16 (7R) -7-benzyl-N- (cyclohexylmethyl) -9- (naphthalen-l- ylmethyl) -4, 8-dioxooctahydropyrimido [1, 2 -a] [1, 4] diazepine- 1 (2H) - carboxamide

ID-17

(7R) -9- (4 -aminobutyl) -7- (4 -hydroxybenzyl) -N-isobutyl-4, 8- dioxooctahydropyrimido [1, 2-a] [1, 4]diazepine-l (2H) -carboxamide ID-18

(7R) -7- (4-hydroxybenzyl) -4, 8-dioxo-9- (pyridin-4-ylmethyl) - N- (thiophen-2-ylmethyl) octahydropyrimido [1, 2-a] [1, 4] diazepine- 1 (2H) -carboxamide ID-19 isobutyl (7R) -7-benzyl-4, 8-dioxo-9- (pyridin-4- ylmethyl) octahydropyrimido [1, 2-a] [1, 4] diazepine-1 (2H) - carboxylate ID-20

(8R) -N-benzyl-8-isopropyl-6- (naphthalen-2-ylmethyl) -7, 11- dioxo-4a, 5, 6, 7, 8, 9-hexahydrothieno [3 ' , 2 ' : 4, 5]pyrimido [1, 2- a] [1, 4] diazepine-4 (11H) -carboxamide ID-21

(8R) -6, 8-dibenzyl-7, 11-dioxo-N- (pyridin-4-ylmethyl) - 4a, 5, 6, 7, 8, 9-hexahydrothieno [3 ' , 2 ' : 4, 5]pyrimido [1, 2- a] [1, 4] diazepine-4 (11H) -carboxamide ID-22

(8R) -8- (4-hydroxybenzyl) -6- (naphthalen-l-ylmethyl) -7, 11- dioxo-N-phenethyl-4a, 5, 6, 7, 8, 9- hexahydrothieno [3 ' , 2 ' : 4, 5]pyrimido [1, 2-a] [1, 4] diazepine-4 (11H) - carboxamide

ID-23

(8R) -8-benzyl-7, ll-dioxo-N-phenethyl-6- (quinolin-8- ylmethyl) -4a, 5, 6, 7, 8, 9-hexahydrothieno [3 ' , 2 ' : 4, 5] pyrimido [1, 2- a] [1, 4] diazepine-4 (11H) -carboxamide ID-24

(8R) -6-butyl-8-isobutyl-N- (naphthalen-l-ylmethyl) -7, 11- dioxo-4a, 5, 6, 7, 8, 9-hexahydrothieno [3 ' , 2 ' : 4, 5]pyrimido [1, 2- a] [1, 4] diazepine-4 (11H) -carboxamide ID-25 (8R) -8-isobutyl-6-isopentyl-N- (naphthalen-l-ylmethyl) - 7, ll-dioxo-4a, 5, 6, 7, 8, 9-hexahydrothieno [3 ' , 2 ' : 4, 5] pyrimido [1, 2- a] [1, 4] diazepine-4 (11H) -carboxamide ID-26

(8R) -8- (4 -hydroxybenzyl) -6-isopentyl-N- (naphthalen-l- ylmethyl) -7, ll-dioxo-4a, 5, 6, 7, 8, 9- hexahydrothieno [3 ' , 2 ' : 4, 5] pyrimido [1, 2-a] [1, 4] diazepine-4 (11H) - carboxamide

ID-27

(8R) -6- (cyclohexylmethyl) -8- (4 -hydroxybenzyl) -N- ( naphthalen-l-ylmethyl) -7, ll-dioxo-4a, 5, 6, 7, 8, 9- hexahydrothieno [ 3 ' , 2 ' : 4, 5] pyrimido [1, 2-a] [1, 4] diazepine-4 (11H) - carboxamide

ID-28

(8R) -6- (4 -aminobutyl) -8-isobutyl-N- (naphthalen-l- ylmethyl) -7, ll-dioxo-4a, 5, 6, 1 , 8, 9- hexahydrothieno [3 ' , 2 ’ : 4, 5]pyrimido [l, 2-a] [1, 4] diazepine-4 (11H) - carboxamide

ID-29

(8R) -N- (3, 3 -diphenylpropyl) -8-methyl-6- (naphthalen-2- ylmethyl) -7, ll-dioxo-4a, 5, 6, 7, 8, 9- hexahydrothieno [3 ' , 2 ' : 4, 5] pyrimido [1, 2-a] [1, 4] diazepine-4 (11H) - carboxamide

ID-30

(8R) -N- (cyclohexylmethyl) -8- (4 -hydroxybenzyl) -7, 11-dioxo- 6- (quinolin-8-ylmethyl) -4a, 5, 6, 7, 8, 9- hexahydrothieno [3 ' , 2 ' : 4, 5]pyrimido [l, 2-a] [1, 4] diazepine-4 (11H) - carboxamide

ID-31

(8R) -N-isobutyl-8-methyl-7, ll-dioxo-6- (pyridin-4- ylmethyl) -4a, 5, 6, 7, 8, 9-hexahydrothieno [3 ' , 2 ' : 4, 5] pyrimido [1, 2— a] [1, 4] diazepine-4 (11H) -carboxamide ID-32

(8R) -N- (benzo [d] [1, 3] dioxol-5-ylmethyl) -6-butyl-8- (4- hydr oxybenzyl) -7, ll-dioxo-4a, 5, 6, 7, 8, 9- hexahydrothieno [ 3 ' , 2 ' : 4, 5] pyrimido [1, 2-a] [1, 4] diazepine-4 (11H) - carboxamide

ID-33 (8R) -N- (benzo [d] [1, 3] dioxol-5-ylmethyl) -8- (4- hydroxybenzyl) -6-isopentyl-7, ll-dioxo-4a, 5, 6, 7, 8, 9- hexahydrothieno [3 ' , 2 ' : 4, 5]pyrimido [1, 2-a] [1, 4] diazepine-4 (11H) - carboxamide

ID-34

(8R) -N- (benzo [d] [1, 3] dioxol-5-ylmethyl) -8-benzyl-6- isopentyl-7, ll-dioxo-4a, 5, 6, 7, 8, 9- hexahydrothieno [ 3 ' , 2 ' : 4, 5] pyrimido [1, 2-a] [1, 4] diazepine-4 (11H) - carboxamide

ID-35

(8R) -8-isopropyl-6- (naphthalen-2-ylmethyl) -7, 11-dioxo-N- (thiophen-2-ylmethyl) -4a, 5, 6, 7, 8, 9- hexahydrothieno [3 ' , 2 ' : 4, 5]pyrimido [1, 2-a] [1, 4] diazepine-4 (11H) - carboxamide

ID-36

(8R) -6-butyl-8- (4 -hydroxybenzyl) -N- (4 -methylbenzyl) -7, 11- dioxo-4a, 5, 6, 7, 8, 9-hexahydrothieno [3 ’ , 2 ' : 4, 5]pyrimido [1, 2- a] [1, 4] diazepine-4 (11H) -carboxamide ID-37

(8R) -8- (4 -hydroxybenzyl) -6-isopentyl-N- (4 -methylbenzyl) - 7, ll-dioxo-4a, 5, 6, 7, 8, 9-hexahydrothieno [3 ' , 2 ' : 4, 5]pyrimido [1, 2- a] [1, 4] diazepine-4 (11H) -carboxamide ID-38 isobutyl (8R) -8- (4 -hydroxybenzyl) -6- ( naphtha len-1- ylmethyl) -7, ll-dioxo-4a, 5, 6, 7, 8, 9- hexahydrothieno [ 3 ' , 2 ' : 4, 5]pyrimido [1, 2-a] [1, 4] diazepine-4 (11H) — carboxylate ID-39

3- ( (3R, 7R) -3-benzyl-l- ( (4 -hydroxyphenethoxy) carbonyl) -9- methyl-4 , 8 -dioxooctahydro- 1H- [1, 2, 4] oxadiazino [4, 3- a] [1, 4] diazepin-7-yl) propanoic acid ID-40

3- ( (3R, 7R) -3- (3-amino-3-oxopropyl) -1-

( (benzyloxy) carbonyl) -9-methy.l-4, 8 -dioxooct ahydro-lH- [l, 2, 4] oxadiazino [4, 3-a] [1, 4 ] diazepin-7-yl) propanoic acid ID-41 3- ( (7R) -1- ( (benzyloxy) carbonyl) -3, 3, 9-trimethyl-4, 8- dioxooctahydro-lH- [1, 2, 4] oxadiazino [4, 3-a] [1, 4] diazepin-7- yl) propanoic acid ID-42

3- ( (7 ' R) -1 ' - ( (benzyloxy) carbonyl) -9 ' -methyl-4 ' , 8 ' - di oxohexahydro- 1 ' H, 4 ' H-spiro [ cyclobutane- 1, 3 ' -

[1.2. 4] oxadiazino [4, 3-a] [ 1, 4] diazepin] -7 ' -yl) propanoic acid ID-43

3- ( (7R) -1- (benzylsulfonyl) -9-methyl-4, 8-dioxooctahydro-lH-

[1.2. 4] oxadiazino [4, 3-a] [1, 4 ] diazepin-7-yl) propanoic acid ID-44 benzyl (7R) -9- (l-acetylpiperidin-4-yl) -7-isobutyl-3, 3- dimethyl-4 , 8-dioxooctahydro-lH- [1, 2, 4] oxadiazino [4, 3- a] [l, 4] diazepine-l-carboxylate ID-45 benzyl (7 ' R) -9 ' - (l-acetylpiperidin-4-yl) -7 ' -isobutyl - 4 ' , 8 ' -dioxohexahydro- 1 ' H, 4 ' H-spiro [ cyclobutane- 1, 3 ' -

[1. 2. 4] oxadiazino [4, 3-a] [1, 4] diazepine] -1 ' -carboxylate

Experimental Example: Notch assay

We used the CellSensor T-REx™ NICD CSL-bla HeLa cell line, which was engineered by lentiviral transduction of HeLa cells with a Notch response element driving beta-lactamase reporter gene expression (CSL-bla) along with DOX (doxycycline) -inducible NICD (Notch intracellular domain) constructs. Addition of DOX to these cells allows for regulated NICD transcription factor expression and subsequent beta-lactamase expression.

Specifically, the following protocol was used.

NOTCH ASSAY PROTOCOL

1. Plate Cells: 32 μL/well of HeLa /T-REx™ NICD CSL-bla cells at 10 ³ cells/well complete medium into 384-well plate.

2. Prepare 10X compounds in assay medium.

3. Add 4 μL compounds or 1% DMSO in assay medium to the cells. 4. Add 4 μL 10x Doxycycline in Assay Medium to the treated wells, and 4 μL Assay Medium to the Untreated and cell free control wells .

5. Incubate the assay plate in a humidified 37°C/5% CO ₂ incubator for 16-20 hours.

6. Preparation of 6X LiveBLAzer“-FRET B/G Substrate (CCF4-AM) Mixture according to the manual and cell loading should be done in the absence of direct strong lighting.

7. Remove assay plate from the humidified 37°C/5% CO ₂ incubator. Add 8 μl of 6X Substrate Mixture from Step 5 to each well. Cover the plate to protect it from light and evaporation.

. Incubate at room temperature for 4hours .

8. Reading an Assay Plate using the following filter selections:

9. Data analysis: Use the assay plate layout to identify the location of the Cell-free wells. These control wells are used for background subtraction. Determine the average emission from the Cell-free wells at both 460 nm (Average Blue Background) and 530 nm (Average Green Background) . Subtract the Average Blue Background (data collected at 460 nm) from all of the blue emission data. Subtract the Average Green background (data collected at 530 nm) from all of the green emission data. Calculate the Blue/Green Emission Ratio for each well, by dividing the background-subtracted blue emission values by the background-subtracted green emission values.

The results are shown in Table 6. [Table 6]

INDUSTRIAL APPLICABILITY

The compound of the present invention inhibits Notch signal transduction, and thus can be used for treating diseases involving Notch signal transduction.

Although only some exemplary embodiments of this invention have been described in detail above, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. Accordingly, all such modifications are intended to be included within the scope of this invention.

This application is based on US provisional patent application No. 63/329, 657 (filing date: April 11, 2022) filed in US, the contents of which are incorporated in full herein.